US20100150994A1 - Amphiphilic entity nanoparticles - Google Patents

Amphiphilic entity nanoparticles Download PDF

Info

Publication number
US20100150994A1
US20100150994A1 US12/517,154 US51715407A US2010150994A1 US 20100150994 A1 US20100150994 A1 US 20100150994A1 US 51715407 A US51715407 A US 51715407A US 2010150994 A1 US2010150994 A1 US 2010150994A1
Authority
US
United States
Prior art keywords
nanoparticle composition
particles
composition
approximately
nanoparticle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/517,154
Other languages
English (en)
Inventor
Timothy Kotyla
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anterios Inc
Original Assignee
Anterios Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anterios Inc filed Critical Anterios Inc
Priority to US12/517,154 priority Critical patent/US20100150994A1/en
Assigned to ANTERIOS, INC. reassignment ANTERIOS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KOTYLA, TIMOTHY
Publication of US20100150994A1 publication Critical patent/US20100150994A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0291—Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/11—Encapsulated compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/678—Tocopherol, i.e. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/85—Polyesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41—Particular ingredients further characterized by their size
    • A61K2800/413—Nanosized, i.e. having sizes below 100 nm
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Definitions

  • Nanoparticles are often proposed for use as a delivery mechanism for a biologically active agent, such as a pharmaceutical. Frequently, it has been challenging to incorporate (or “load”) the biologically active agent into the nanoparticle because the amount that can be incorporated is limited or that it takes a great deal of time to incorporate the material (through, for example, diffusion). This challenge can limit the practical or commercial utility of the nanoparticle as a delivery mechanism for a biologically active agent.
  • the present invention provides nanoparticle compositions comprising amphiphilic entity (AE) nanoparticles.
  • the nanoparticle compositions are uniform.
  • the total particle distribution is encompassed within a particular range of particle diameter sizes (discussed in more detail below); in some embodiments, a portion of the total particle distribution is outside of the particular range.
  • the present invention provides AE nanoparticles and pharmaceutical compositions comprising AE nanoparticles.
  • AE nanoparticles comprise one or more amphiphilic entities.
  • the AE nanoparticles may comprise one or more dispersion media, surfactants, biologically active agents, and/or release-retarding ingredients.
  • the AE nanoparticles are smaller than 1000 nanometers, 500 nanometers, 200 nanometers, or 100 nanometers in diameter.
  • the present invention provides systems, including methods, reagents, and/or compositions, for manufacturing AE nanoparticles.
  • AE nanoparticle compositions may be generated by exposure to high shear forces; in some embodiments, AE nanoparticle compositions may be generated high pressure homogenization; in some embodiments, AE nanoparticle compositions may be generated by cavitation; in some embodiments, AE nanoparticle compositions may be generated by microfluidization.
  • commercially available equipment such the Microfluizider®, may be used to generate high shear forces.
  • methods of manufacturing AE nanoparticles generally comprise steps of preparing a premix of one or more amphiphilic entities and applying high shear force to the premix.
  • the premix generally contains one or ore amphiphilic entities and one or more dispersion media.
  • the premix may optionally comprise one or more surfactants, biologically active agents, and/or release-retarding ingredients.
  • the amphiphilic entities of the premix assemble into particles (e.g. nanoparticles, microparticles, and/or micelles) before application of high shear force.
  • the amphiphilic entities of the premix do not assemble into particles before the application of high shear force.
  • the present invention provides improvements over traditional methods of manufacturing nanoparticles.
  • the use of mechanical energy replaces or minimizes the requirement to use costly and toxic chemical solvents, increases the speed and reaction yield, reduces the overall cost of the synthetic reaction, thereby increasing the commercial utility of AE nanoparticles.
  • the use of high shear force allows for increased loading capacity of the nanoparticle as compared to traditional methods of forming nanoparticles.
  • loading of agents within or on the surface of nanoparticles relies on diffusion of the agent to the interior and/or to the surface of the nanoparticle.
  • the present invention encompasses the recognition that subjecting particles (e.g. nanoparticles, microparticles, and/or micelles) to high shear force is a method of manufacturing nanoparticles that is inexpensive and efficient and does not utilize toxic residual components.
  • the AE nanoparticles are completely free or substantially free of toxic components.
  • the nanoparticle compositions comprising AE nanoparticles are completely free or substantially free of toxic components.
  • the present invention further encompasses the recognition that subjecting particles (e.g. nanoparticles, microparticles, and/or micelles) to high shear force generates nanoparticles with an increased loading capacity relative to traditional methods of making nanoparticles.
  • the present invention provides a method of delivering a composition, substance, or biologically active agent to a subject.
  • the composition, substance, or biologically active agent may be delivered via any route.
  • the composition, substance, or biologically active agent is delivered transdermally (or topically).
  • the invention provides methods and compositions for transdermally delivering a biologically active agent to a subject by administering to the subject nanoparticle compositions comprising AE nanoparticles to the surface of the subject's skin, wherein the biologically active agent is encapsulated within and/or bound to the surface of the AE nanoparticles.
  • the present invention encompasses the discovery that AE nanoparticles of the present invention can achieve transdermal delivery of a biologically active agent without changing or altering the structure of the skin. For example, abrasive agents or agents that erode the top layer of the skin (whether chemical, mechanical, electrical, magnetic, etc.) are not required to achieve transdermal delivery of a biologically active agent.
  • a composition for transdermal delivery of a biologically active agent may be in the form of a transdermal patch.
  • inventive compositions comprising AE nanoparticles for transdermal delivery of a biologically active agent may be used in an application device that permits application of the composition to a target site on the skin without applying the composition to non-target site areas of the skin.
  • the biologically active agent comprises a biological polymer.
  • the polymer is DNA, RNA, or a protein.
  • the protein comprises multiple proteins and/or protein complexes.
  • the biologically active agent delivered according to the present invention is one or more botulinum toxin peptides, polypeptides and/or protein complexes.
  • the botulinum toxin may be one or more of botulinum toxin serotypes A, B, C 1 , C 2 , D, E, F, or G.
  • the botulinum toxin may be an isolated and/or purified botulinum toxin.
  • the botulinum toxin may be a partially-isolated and/or partially-purified botulinum toxin. In some embodiments, the botulinum toxin may be a native botulinum complex. In some embodiments, the botulinum toxin may be associated with non-toxin proteins. In some embodiments, the botulinum toxin may be a recombinantly-made botulinum toxin.
  • the present invention provides methods of treating facial wrinkles (e.g. wrinkles involving the forehead, glabellar, rhytids, and/or periorbital regions); hyperkinetic facial lines; platysma bands; neuromuscular disorders and conditions involving muscular spasm and/or contracture (e.g. facial palsy, blepharospasm, cerebral palsy, strabismus, and/or dystonia); prostate hyperplasia; hyperhidrosis; headache, and/or temporomandibular joint diseases and disorders (TMJ, also known as “lockjaw”).
  • Such methods generally involve administering to a subject nanoparticle compositions comprising AE nanoparticles for the transdermal delivery of a botulinum toxin or botulinum toxin complex.
  • the present invention provides methods of treating facial wrinkles (e.g. wrinkles involving the forehead, glabellar, rhytids, and/or periorbital regions), hyperkinetic facial lines, and/or platysma bands.
  • facial wrinkles e.g. wrinkles involving the forehead, glabellar, rhytids, and/or periorbital regions
  • nanoparticle compositions comprising AE nanoparticles for the transdermal delivery of a biologically active agent may be used to treat facial wrinkles.
  • nanoparticle compositions comprising AE nanoparticles for the transdermal delivery of a botulinum toxin or botulinum toxin complex may be used to treat facial wrinkles
  • facial wrinkles may include glabellar wrinkles, facial lines (e.g.
  • Such methods generally involve administering to a subject nanoparticle compositions comprising AE nanoparticles for the transdermal delivery of a botulinum toxin or botulinum toxin complex.
  • the present invention does not provide methods of treating prostate hyperplasia. In some embodiments, the present invention does not provide methods of treating neuromuscular disorders and conditions involving muscular spasm and/or contracture. In some embodiments, the present invention does not provide methods of treating hyperhidrosis. In some embodiments, the present invention does not provide methods of treating headache. In some embodiments, the present invention does not provide methods of treating TMJ.
  • Abrasion refers to any means of altering, disrupting, removing, or destroying the top layer of the skin.
  • abrasion refers to a mechanical means of altering, disrupting, removing, or destroying the top layer of the skin.
  • abrasion refers to a chemical means of altering, disrupting, removing, or destroying the top layer of skin.
  • agents such as exfoliants, fine particles (e.g. magnesium or aluminum particles), acids (e.g. alpha-hydroxy acids or beta-hydroxy acids), alcohols, may cause abrasion.
  • permeation enhancers such as those described, for example, by Donovan (e.g.
  • amino acid in its broadest sense, refers to any compound and/or substance that can be incorporated into a polypeptide chain.
  • an amino acid has the general structure H 2 N—C(H)(R)—COOH.
  • an amino acid is a naturally-occurring amino acid.
  • an amino acid is a synthetic amino acid; in some embodiments, an amino acid is a D-amino acid; in some embodiments, an amino acid is an L-amino acid.
  • Standard amino acid refers to any of the twenty standard L-amino acids commonly found in naturally occurring peptides.
  • Nonstandard amino acid refers to any amino acid, other than the standard amino acids, regardless of whether it is prepared synthetically or obtained from a natural source.
  • synthetic amino acid encompasses chemically modified amino acids, including but not limited to salts, amino acid derivatives (such as amides), and/or substitutions.
  • Amino acids, including carboxy- and/or amino-terminal amino acids in peptides, can be modified by methylation, amidation, acetylation, and/or substitution with other chemical groups that can change the peptide's circulating half-life without adversely affecting their activity. Amino acids may participate in a disulfide bond.
  • amino acid is used interchangeably with “amino acid residue,” and may refer to a free amino acid and/or to an amino acid residue of a peptide. It will be apparent from the context in which the term is used whether it refers to a free amino acid or a residue of a peptide.
  • amphiphilic entity refers to a chemical entity possessing both hydrophilic and hydrophobic nature. As used herein, the terms “amphiphilic” and “amphipathic” can be used interchangeably.
  • the amphiphilic entities of an AE nanoparticle are biocompatible. Biocompatible amphiphilic entities are not significantly toxic to cells.
  • the amphiphilic entities of an AE nanoparticle are biodegradable. Biodegradable amphiphilic entities are broken down by the cellular machinery and/or by hydrolysis into components that the cells can either reuse or dispose of without significant toxic effect.
  • a biodegradable amphiphilic entity and its biodegradation byproducts are biocompatible.
  • the amphiphilic entity is non-immunogenic.
  • an amphiphilic entity may comprise one or more individual compounds or molecules that is itself amphiphilic.
  • an amphiphilic entity may comprise one or more individual components that is not itself amphiphilic but that has some hydrophilic or hydrophobic character. Typically, the individual components are associated with one another such that the assemblage of the individual components is amphiphilic.
  • animal refers to any member of the animal kingdom. In some embodiments, “animal” refers to humans, at any stage of development. In some embodiments, “animal” refers to non-human animals, at any stage of development. In certain embodiments, the non-human animal is a mammal (e.g., a rodent, a mouse, a rat, a rabbit, a monkey, a dog, a cat, a sheep, cattle, a primate, and/or a pig). In some embodiments, animals include, but are not limited to, mammals, birds, reptiles, amphibians, fish, and/or worms. In some embodiments, an animal may be a transgenic animal, genetically-engineered animal, and/or a clone.
  • mammal e.g., a rodent, a mouse, a rat, a rabbit, a monkey, a dog, a cat, a sheep, cattle, a primate, and/or a pig.
  • Antibody refers to an immunoglobulin, whether naturally produced, synthetically produced, or both.
  • the antibody may be a member of any immunoglobulin class, including any of the human classes: IgG, IgM, IgA, IgD, and/or IgE.
  • the antibody may be a fragment of an antibody such as an Fab′; F(ab′) 2 ; scFv (single-chain variable) and/or any other fragment that retains an antigen binding site; and/or a recombinantly-produced scFv fragment, including recombinantly-produced fragments (see, e.g., Allen, 2002 , Nat Rev Cancer, 2:750 and references therein; incorporated herein by reference).
  • the term refers to “humanized” antibodies, which include sequences of human origin.
  • “humanized” antibodies are characterized by a variable domain of rodent origin fused to a constant domain of human origin, thus retaining the specificity of the rodent antibody.
  • human domains may be generated in rodents whose genome incorporates human immunoglobulin genes (see, e.g., Harlow et al., Antibodies: A Laboratory Manual , Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1988; incorporated herein by reference).
  • An antibody may be polyclonal or monoclonal.
  • biologically active agent refers to any substance that has activity in a biological system and/or organism. For instance, a substance that, when administered to an organism, has a biological effect on that organism, is considered to be biologically active. In particular embodiments, where a protein or polypeptide is biologically active, a portion of that protein or polypeptide that shares at least one biological activity of the protein or polypeptide is typically referred to as a “biologically active” portion.
  • Characteristic portion As used herein, the phrase a “characteristic portion” of a substance, in the broadest sense, is one that shares some degree of sequence and/or structural identity and/or at least one functional characteristic with the relevant intact substance.
  • a “characteristic portion” of a protein or polypeptide is one that contains a continuous stretch of amino acids, or a collection of continuous stretches of amino acids, that together are characteristic of a protein or polypeptide. In some embodiments, each such continuous stretch generally will contain at least 2, 5, 10, 15, 20 or more amino acids.
  • a characteristic portion is one that, in addition to the sequence identity specified above, shares at least one functional characteristic with the relevant intact protein. In some embodiments, the characteristic portion may be biologically active.
  • Dispersion medium refers to a liquid medium in which particles (e.g., AE nanoparticles) are dispersed. In general, a dispersion is formed when at least two immiscible materials are combined.
  • An “oil-in-water” dispersion is one in which oily particles are dispersed within an aqueous dispersion medium.
  • a “water-in-oil” dispersion is one in which aqueous particles are dispersed within an oily dispersion medium.
  • a dispersion can be formed from any two immiscible media and is not limited strictly to combinations of aqueous and oily media.
  • the term “dispersion medium” therefore applies broadly to any dispersion medium notwithstanding that it is common to refer to “aqueous” and “oily” categories.
  • Encapsulated The term “encapsulated” (also “encapsulate” or “encapsulating”) is used herein to mean that the encapsulated entity is completely surrounded by another material.
  • a biologically active agent may be encapsulated within a nanoparticle in an inventive composition. Such encapsulation may be achieved, for example, during formation of a nanoparticle composition, for example during exposure to high shear force.
  • expression of a nucleic acid sequence refers to one or more of the following events: (1) production of an RNA template from a DNA sequence (e.g., by transcription); (2) processing of an RNA transcript (e.g., by splicing, editing, 5′ cap formation, and/or 3′ end formation); (3) translation of an RNA into a polypeptide or protein; (4) post-translational modification of a polypeptide or protein.
  • gene has its meaning as understood in the art. It will be appreciated by those of ordinary skill in the art that the term “gene” may include gene regulatory sequences (e.g., promoters, enhancers, etc.) and/or intron sequences. It will further be appreciated that definitions of gene include references to nucleic acids that do not encode proteins but rather encode functional RNA molecules such as tRNAs.
  • gene generally refers to a portion of a nucleic acid that encodes a protein; the term may optionally encompass regulatory sequences, as will be clear from context to those of ordinary skill in the art. This definition is not intended to exclude application of the term “gene” to non-protein-coding expression units but rather to clarify that, in most cases, the term as used in this document refers to a protein-coding nucleic acid.
  • Gene product or expression product generally refers to an RNA transcribed from the gene (pre- and/or post-processing) or a polypeptide (pre- and/or post-modification) encoded by an RNA transcribed from the gene.
  • homology As used herein, the terms “homology” and “identity” are used interchangeably and refer to the overall relatedness between polymeric molecules, e.g. between nucleic acid molecules (e.g. DNA molecules and/or RNA molecules) and/or between polypeptide molecules. Calculation of the percent homology or identity of two nucleic acid sequences can be performed by aligning the two sequences for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second nucleic acid sequences for optimal alignment and non-homologous sequences can be disregarded for comparison purposes).
  • the length of a sequence aligned for comparison purposes is at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% or 100% of the length of the reference sequence.
  • Nucleotides at corresponding nucleotide positions are then compared. When a position in the first sequence is occupied by the same nucleotide as the corresponding position in the second sequence, then the molecules are identical (or homologous) at that position.
  • the percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which needs to be introduced for optimal alignment of the two sequences.
  • the comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm.
  • the percent identity between two nucleotide sequences can be determined using the algorithm of Meyers and Miller (CABIOS, 1989, 4: 11-17; incorporated herein by reference), which has been incorporated into the ALIGN program (version 2.0) using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.
  • the percent identity between two nucleotide sequences can, alternatively, be determined using the GAP program in the GCG software package using an NWSgapdna.CMP matrix.
  • Hydrophilic As used herein, a “hydrophilic” substance is a substance that may be soluble in polar dispersion media. In some embodiments, a hydrophilic substance can transiently bond with polar dispersion media. In some embodiments, a hydrophilic substance transiently bonds with polar dispersion media through hydrogen bonding. In some embodiments, the polar dispersion medium is water. In some embodiments, a hydrophilic substance may be ionic. In some embodiments, a hydrophilic substance may be non-ionic. In some embodiments, a hydrophilic substance may dissolve more readily in water, polar dispersion media, or hydrophilic dispersion media than in oil, non-polar dispersion media, or hydrophobic dispersion media.
  • a hydrophilic substance may dissolve less readily in oil, non-polar dispersion media, or hydrophobic dispersion media than in water, polar dispersion media, or hydrophilic dispersion media.
  • a substance is hydrophilic relative to another substance because it is more soluble in water, polar dispersion media, or hydrophilic dispersion media than is the other substance.
  • a substance is hydrophilic relative to another substance because it is less soluble in oil, non-polar dispersion media, or hydrophobic dispersion media than is the other substance.
  • Hydrophobic As used herein, a “hydrophobic” substance is a substance that may be soluble in non-polar dispersion media. In some embodiments, a hydrophobic substance is repelled from polar dispersion media. In some embodiments, the polar dispersion medium is water. In some embodiments, hydrophobic substances are non-polar. In some embodiments, a hydrophobic substance may dissolve more readily in oil, non-polar dispersion media, or hydrophobic dispersion media than in water, polar dispersion media, or hydrophilic dispersion media.
  • a hydrophobic substance may dissolve less readily in water, polar dispersion media, or hydrophilic dispersion media than in oil, non-polar dispersion media, or hydrophobic dispersion media.
  • a substance is hydrophobic relative to another substance because it is more soluble in oil, non-polar dispersion media, or hydrophobic dispersion media than is the other substance.
  • a substance is hydrophobic relative to another substance because it is less soluble in water, polar dispersion media, or hydrophilic dispersion media than is the other substance.
  • the phrase “delivered in conjunction with” refers to the co-delivery of two or more substances or agents.
  • the phrase is used herein in reference to delivery of a biologically active agent with inventive AE nanoparticles and/or nanoparticle compositions.
  • a substance or agent is delivered in conjunction with AE nanoparticles when the substance or agent is combined with AE nanoparticles and/or nanoparticle compositions; is encapsulated or completely surrounded by AE nanoparticles; is embedded within an AE nanoparticle micellar membrane; and/or is associated with the outer surface of an AE nanoparticle micellar membrane.
  • a substance or agent to be delivered in conjunction with AE nanoparticles and/or nanoparticle compositions may or may not be covalently linked to the AE nanoparticles and/or nanoparticle compositions.
  • a substance or agent to be delivered in conjunction with nanoparticles and/or nanoparticle compositions may or may not be attached to the AE nanoparticles and/or nanoparticle compositions by adsorption forces.
  • Isolated refers to a substance and/or entity that has been (1) separated from at least some of the components with which it was associated when initially produced (whether in nature and/or in an experimental setting), and/or (2) produced, prepared, and/or manufactured by the hand of man. Isolated substances and/or entities may be separated from at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or more of the other components with which they were initially associated. In some embodiments, isolated substances and/or entities are more than 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% pure.
  • Microfluidized means exposed to high shear forces. In some embodiments, such exposure to high shear forces is accomplished by exposure to high pressure; in some embodiments such high pressure is within the range of about 15,000 to about 26,000 psi. In some embodiments, such exposure to high shear forces is accomplished by cavitation. In some embodiments, such exposure to high shear forces is accomplished by passing a sample through an instrument such as, for example, a Microfluidizer® (Microfluidics Corporation/MFIC Corporation) or other like device that may be useful in creating a uniform nanoparticle composition.
  • a Microfluidizer® Microfluidics Corporation/MFIC Corporation
  • a sample is microfluidized through exposure to high shear forces for a period of time less than about 10 minutes. In some embodiments, the period of time is less than about 9, 8, 7, 6, 5, 4, 3, 2, or 1 minute(s). In some embodiments, the period of time is within the range of about 1-2 minutes. In some embodiments, the period of time is less than 1 minute. In some embodiments, the period of time is about 30 seconds. In some embodiments of the invention, a sample is “microfluidized” through a single exposure to high shear forces; such embodiments are referred to as “single pass” microfluidization.
  • Nanoparticle refers to any particle having a diameter of less than 1000 nanometers (nm). In some embodiments, a nanoparticle has a diameter of less than 300 nm, as defined by the National Science Foundation. In some embodiments, a nanoparticle has a diameter of less than 100 nm as defined by the National Institutes of Health. In some embodiments, nanoparticles are micelles in that they comprise an enclosed compartment, separated from the bulk solution by a micellar membrane. A “micellar membrane” comprises amphiphilic entities which have aggregated to surround and enclose a space or compartment (e.g., to define a lumen).
  • Nanoparticle composition refers to any substance that contains at least one AE nanoparticle.
  • a nanoparticle composition is a uniform collection of AE nanoparticles.
  • nanoparticle compositions are dispersions or emulsions. In general, a dispersion or emulsion is formed when at least two immiscible materials are combined.
  • An “oil-in-water” dispersion is one in which oily particles (or hydrophobic or non-polar) are dispersed within an aqueous dispersion medium.
  • a “water-in-oil” dispersion is one in which aqueous (or hydrophilic or polar) particles are dispersed within an oily dispersion medium.
  • a dispersion can be formed from any two immiscible media and is not limited strictly to combinations of aqueous and oily media.
  • the term “dispersion medium” therefore applies broadly to any dispersion medium notwithstanding that it is common to refer to “aqueous” and “oily” categories.
  • nanoparticle compositions are nanoemulsions.
  • nanoparticle compositions comprise micelles.
  • a nanoparticle composition is stable.
  • a nanoparticle composition includes one or more biologically active agents to be delivered in conjunction with the AE nanoparticles.
  • not contaminated with when used herein to refer to a nanoparticle composition, is synonymous with “substantially free of” and describes a nanoparticle composition containing no more than about 50% of the recited material. For example, if a nanoparticle composition is said to be “substantially free of” particles whose diameter is outside of a stated range, then no more than about 50% of the particles in that composition have diameters outside of the range. In some embodiments, no more than 25% of the particles are outside of the range.
  • nucleic acid refers to any compound and/or substance that can be incorporated into an oligonucleotide chain.
  • nucleic acid encompasses RNA as well as single and/or double-stranded DNA and/or cDNA.
  • nucleic acid “DNA,” “RNA,” and/or similar terms include nucleic acid analogs, i.e. analogs having other than a phosphodiester backbone.
  • peptide nucleic acids which are known in the art and have peptide bonds instead of phosphodiester bonds in the backbone, are considered within the scope of the present invention.
  • nucleotide sequence encoding an amino acid sequence includes all nucleotide sequences that are degenerate versions of each other and/or encode the same amino acid sequence. Nucleotide sequences that encode proteins and/or RNA may include introns.
  • nutraceutical refers to any substance thought to provide medical, health, or biological benefits.
  • nutraceuticals may prevent disease.
  • nutraceuticals may provide basic nutritional value.
  • a nutraceutical is a food or part of a food.
  • a nutraceutical agent may be a class of isolated nutrients, dietary supplements, vitamins, minerals, herbs, fortified foods, healing foods, genetically engineered foods, and processed foods. Nutraceuticals may also be known as “phytochemical foods” or “functional foods.”
  • a “patient,” or “subject,” as used herein, means an animal.
  • the animal is a mammal, commonly a human.
  • premix refers to any combination of components that is subsequently used to generate a nanoparticle composition according to the present invention.
  • a premix is any collection of ingredients that, when subjected to high shear forces, generates AE nanoparticles according to the present invention.
  • a premix contains two or more immiscible solvents.
  • a premix contains components that self-assemble into microparticles or nanoparticles.
  • a premix contains components that self-assemble into micelles.
  • a premix contains one or more peptides as described in PCT application serial number PCT/US07/______ entitled “Peptide Nanoparticles and Uses Therfor,” filed Nov. 30, 2007.
  • a premix contains one or more unmodified peptides; in some embodiments, a premix contains at least one other biologically active agent.
  • a premix is agitated, mixed, and/or stirred; in some embodiments, a premix is agitated, mixed, and/or stirred prior to being subjected to high shear force.
  • a premix comprises at least one solubilized component (i.e., at least one component that is in solution); in some such embodiments, the premix is subjected to high shear force after such solubilization is achieved.
  • a substance and/or entity is “pure” if it is substantially free of other components.
  • a preparation that contains more than about 90% of a particular substance and/or entity is typically considered to be a pure preparation.
  • a substance and/or entity is at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% pure.
  • Shear force refers to a force that is parallel to the face of a material, as opposed to a force that is perpendicular to the face of a material.
  • a composition exposed to high shear forces in order to produce a uniform nanoparticle composition Any method known in the art can be used to generate high shear forces.
  • cavitation is used to generate high shear forces.
  • high pressure homogenization is used to generate high shear forces.
  • high shear force may be administered by exposure to high pressure, for example about 15,000 psi.
  • such high pressure is within the range of about 18,000 to about 26,000 psi; in some embodiments, it is within the range of about 20,000 to about 25,000 psi.
  • a Microfluidizer® Processor (Microfluidics Corporation/MFIC Corporation) or other like device is used to generate high shear force. Microfluidizer® Processors provide high pressure and a resultant high shear rate by accelerating a composition through microchannels (typically having dimensions on the order of 75 microns) at a high velocity (typically in the range of 50 m/s to 300 m/s) for size reduction to the nanoscale range.
  • a sample is exposed to high shear forces for a period of time less than about 10 minutes. In some embodiments, the period of time is less than about 9, about 8, about 7, about 6, about 5, about 4, about 3, about 2, or about 1 minute(s).
  • the period of time is within the range of about 1 to about 2 minutes or less; in some embodiments, the period of time is about 30 seconds.
  • a sample is “microfluidized” through a single exposure to high shear forces; such embodiments are referred to herein as “single pass” microfluidization.
  • Small Molecule In general, a “small molecule” is understood in the art to be an organic molecule that is less than about 5 kilodaltons (Kd) in size. In some embodiments, the small molecule is less than about 3 Kd, about 2 Kd, or about 1 Kd. In some embodiments, the small molecule is less than about 800 daltons (D), about 600 D, about 500 D, about 400 D, about 300 D, about 200 D, or about 100 D. In some embodiments, small molecules are non-polymeric. In some embodiments, small molecules are not proteins, peptides, or amino acids. In some embodiments, small molecules are not nucleic acids or nucleotides. In some embodiments, small molecules are not saccharides or polysaccharides.
  • Kd kilodaltons
  • subject refers to any organism to which a composition of this invention may be administered, e.g., for experimental, diagnostic, prophylactic, and/or therapeutic purposes.
  • Typical subjects include animals (e.g., mammals such as mice, rats, rabbits, non-human primates, and humans; insects; worms; etc.).
  • the term “substantially” refers to the qualitative condition of exhibiting total or near-total extent or degree of a characteristic or property of interest.
  • One of ordinary skill in the biological arts will understand that biological and chemical phenomena rarely, if ever, go to completion and/or proceed to completeness or achieve or avoid an absolute result.
  • the term “substantially” is therefore used herein to capture the potential lack of completeness inherent in many biological and chemical phenomena.
  • Stable when applied to nanoparticle compositions herein, means that the compositions maintain one or more aspects of their physical structure (e.g., size range and/or distribution of particles) over a period of time.
  • a stable nanoparticle composition is one for which the average particle size, the maximum particle size, the range of particle sizes, and/or the distribution of particle sizes (i.e., the percentage of particles above a designated size and/or outside a designated range of sizes) is maintained for a period of time.
  • the period of time is at least about one hour; in some embodiments the period of time is about 5 hours, about 10 hours, about one (1) day, about one (1) week, about two (2) weeks, about one (1) month, about two (2) months, about three (3) months, about four (4) months, about five (5) months, about six (6) months, about eight (8) months, about ten (10) months, about twelve (12) months, about twenty-four (24) months, or longer. In some embodiments, the period of time is within the range of about one (1) day to about twenty-four (24) months, about two (2) weeks to about twelve (12) months, about two (2) months to about five (5) months, etc.
  • a nanoparticle composition is subjected to prolonged storage, temperature changes, and/or pH changes and a majority of the nanoparticles in the population maintain a diameter within a stated range (i.e., for example, between approximately 10 nm-120 nm), the nanoparticle composition is stable.
  • a majority is more than about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, about 99.5%, about 99.6%, about 99.7%, about 99.8%, about 99.9%, or more.
  • a nanoparticle composition comprises one or more biologically active agents (e.g. botulinum toxin)
  • the nanoparticle composition is considered stable if the concentration of biologically active agent is maintained in the composition over the designated period of time under a designated set of conditions.
  • An inventive nanoparticle composition is said to be “substantially free of” particles whose diameter is outside of a stated range when no more than about 50% of the particles in that composition have diameters outside of the range. In some embodiments, no more than 25% of the particles are outside of the range. In some embodiments, no more than 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5% or less of the particles have diameters outside of the stated range.
  • therapeutically effective amount means an amount of inventive AE nanoparticle composition that is sufficient, when administered to a patient suffering from or susceptible to a disease, disorder, and/or condition, to treat the disease, disorder, and/or condition.
  • therapeutic agent refers to any agent that, when administered to a subject, has a therapeutic effect and/or elicits a desired biological and/or pharmacological effect.
  • Toxic solvent refers to any substance that may alter, disrupt, remove, or destroy an animal's tissue.
  • an animal's tissue can include living cells, dead cells, extracellular matrix, cellular junctions, biological molecules, etc.
  • toxic solvents include dimethyl sulfoxide, dimethyl acetimide, dimethyl foramide, chloroform, tetramethyl foramide, acetone, acetates, and alkanes.
  • treatment refers to any administration of a biologically active agent that partially or completely alleviates, ameliorates, relives, inhibits, delays onset of, reduces severity of, and/or reduces incidence of one or more symptoms or features of a particular disease, disorder, and/or condition (e.g., facial wrinkles).
  • a biologically active agent that partially or completely alleviates, ameliorates, relives, inhibits, delays onset of, reduces severity of, and/or reduces incidence of one or more symptoms or features of a particular disease, disorder, and/or condition (e.g., facial wrinkles).
  • Such treatment may be of a subject who does not exhibit signs of the relevant disease, disorder and/or condition and/or of a subject who exhibits only early signs of the disease, disorder, and/or condition.
  • such treatment may be of a subject who exhibits one or more established signs of the relevant disease, disorder and/or condition.
  • Uniform when used herein in reference to a nanoparticle composition, refers to a nanoparticle composition in which the individual nanoparticles have a specified range of particle diameter sizes.
  • a uniform nanoparticle composition is one in which the difference between the minimum diameter and maximum diameter does not exceed approximately 600, approximately 550, approximately 500, approximately 450, approximately 400, approximately 350, approximately 300, approximately 250, approximately 200, approximately 150, approximately 100, approximately 90, approximately 80, approximately 70, approximately 60, approximately 50, or fewer nm.
  • particles (e.g., AE nanoparticles) within inventive uniform nanoparticle compositions have diameters that are smaller than about 600, about 550, about 500, about 450, about 400, about 350, about 300, about 250, about 200, about 150, about 130, about 120, about 115, about 110, about 100, about 90, about 80 nm, or less.
  • particles (e.g., AE nanoparticles) within inventive uniform nanoparticle compositions have diameters within the range of about 10 and about 600 nanometers.
  • particles (e.g., AE nanoparticles) within inventive uniform nanoparticle compositions have diameters within the range of about 10 to about 300, about 10 to about 200, about 10 to about 150, about 10 to about 130, about 10 to about 120, about 10 to about 115, about 10 to about 110, about 10 to about 100, or about 10 to about 90 nm.
  • particles (e.g., AE nanoparticles) within inventive botulinum nanoparticle compositions have an average particle size that is under about 300, about 250, about 200, about 150, about 130, about 120, about 115, about 110, about 100, or about 90 nm.
  • the average particle size is within the range of about 10 to about 300, about 50 to about 250, about 60 to about 200, about 65 to about 150, about 70 to about 130 nm. In some embodiments, the average particle size is about 80 to about 110 nm. In some embodiments, the average particle size is about 90 to about 100 nm. In some embodiments, a majority of the particles (e.g., AE nanoparticles) within inventive uniform nanoparticle compositions have diameters below a specified size or within a specified range.
  • a uniform nanoparticle composition is achieved by microfluidization of a sample.
  • a uniform nanoparticle composition is prepared by exposure to high shear force, e.g., by microfluidization.
  • Vector refers to a nucleic acid molecule which can transport another nucleic acid to which it has been linked.
  • vectors can achieve extra-chromosomal replication and/or expression of nucleic acids to which they are linked in a host cell such as a eukaryotic and/or prokaryotic cell.
  • Vectors capable of directing the expression of operatively linked genes are referred to herein as “expression vectors.”
  • the present invention provides compositions containing AE nanoparticles.
  • the nanoparticle compositions are stable (i.e. the particles of the nanoparticle composition stay within a stated range over time and when subjected to temperature and/or pH changes).
  • the nanoparticle compositions are sterile (i.e. the nanoparticle composition contains no living cellular contaminants).
  • the nanoparticle compositions are bacteria-resistant (i.e. the nanoparticle compositions are characterized by no observable bacterial growth).
  • the nanoparticle compositions comprising AE nanoparticles are completely free or substantially free of toxic components. In some embodiments, the AE nanoparticles are completely free or substantially free of toxic components.
  • the nanoparticle compositions are uniform.
  • a uniform nanoparticle composition comprises a population of particles whose difference between the minimum and maximum diameters does not exceed approximately 600 nm, approximately 550 nm, approximately 500 nm, approximately 450 nm, approximately 400 nm, approximately 350 nm, approximately 300 nm, approximately 250 nm, approximately 200 nm, approximately 150 nm, or approximately 100 nm.
  • AE nanoparticles inventive nanoparticle compositions have diameters that are smaller than about 1000, about 600, about 550, about 500, about 450, about 400, about 350, about 300, about 250, about 200, about 150, about 130, about 120, about 115, about 110, about 100, about 90, about 80, about 50 nm, or less.
  • inventive AE nanoparticles have a diameter of 1 to 1000 nm, 1 to 600 nm, 1 to 500 nm, 1 to 400 nm, 1 to 300 nm, 1 to 200 nm, 1 to 150 nm, 1 to 120 nm, 1 to 100 nm, 1 to 75 nm, 1 to 50 nm, or 1 to 25 nm. In some embodiments, inventive AE nanoparticles have a diameter of 1 to 15 nm, 15 to 200 nm, 25 to 200 nm, 50 to 200 nm, or 75 to 200 nm.
  • the total particle distribution is encompassed within the specified range of particle diameter size. In some embodiments, less than 50%, 25%, 10%, 5%, or 1% of the total particle distribution is outside of the specified range of particle diameter sizes. In some embodiments, less than 1% of the total particle distribution is outside of the specified range of particle diameter sizes. In certain embodiments, the nanoparticle composition is substantially free of particles having a diameter larger than 300 nm, 250 nm, 200 nm, 150 nm, 120 nm, 100 nm, 75 nm, 50 nm, or 25 nm.
  • AE nanoparticles within inventive nanoparticle compositions have an average particle size that is under about 300, about 250, about 200, about 150, about 130, about 120, about 115, about 110, about 100, about 90, or about 50 nm. In some embodiments, the average particle size is within the range of about 10 to about 300, about 50 to about 250, about 60 to about 200, about 65 to about 150, about 70 to about 130 nm. In some embodiments, the average particle size is about 80 to about 110 nm. In some embodiments, the average particle size is about 90 to about 100 nm.
  • inventive nanoparticle compositions are substantially free of particles having a diameter in excess of 300 nm. Specifically, in some embodiments, fewer than 50%, of the nanoparticles in inventive nanoparticle compositions have a diameter in excess of 300 nm. In some embodiments, fewer than 25% of the particles have a diameter in excess of 300 nm. In some embodiments, fewer than 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5% or less of the particles have a diameter in excess of 300 nm. Furthermore, in some embodiments, the nanoparticles in inventive nanoparticle compositions have diameters within the range of 10 to 300 nm.
  • inventive nanoparticle compositions are substantially free of particles having a diameter in excess of 200 nm. Specifically, in some embodiments, fewer than 50%, of the nanoparticles in inventive nanoparticle compositions have a diameter in excess of 200 nm. In some embodiments, fewer than 25% of the particles have a diameter in excess of 200 nm. In some embodiments, fewer than 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5% or less of the particles have a diameter in excess of 200 nm. Furthermore, in some embodiments, the nanoparticles in inventive nanoparticle compositions have diameters within the range of 10 to 200 nm.
  • inventive nanoparticle compositions are substantially free of particles having a diameter in excess of 120 nm. Specifically, in some embodiments, fewer than 50%, of the nanoparticles in inventive nanoparticle compositions have a diameter in excess of 120 nm. In some embodiments, fewer than 25% of the particles have a diameter in excess of 120 nm. In some embodiments, fewer than 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5% or less of the particles have a diameter in excess of 120 nm. Furthermore, in some embodiments, the nanoparticles in inventive nanoparticle compositions have diameters within the range of 10 to 120 nm.
  • a majority of the AE nanoparticles within inventive compositions have diameters below a specified size or within a specified range. In some embodiments, the majority is more than 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or more of the particles in the composition.
  • Zeta potential is a measurement of the electric potential at a shear plane.
  • a shear plane is an imaginary surface separating a thin layer of liquid bound to a solid surface (e.g. the surface of inventive nanoparticles) and showing elastic behavior from the rest of liquid (e.g. liquid dispersion medium) showing normal viscous behavior.
  • inventive AE nanoparticles have a zeta potential ranging between ⁇ 50 mV to +50 mV.
  • inventive AE nanoparticles have a zeta potential ranging between ⁇ 25 mV to +25 mV.
  • inventive AE nanoparticles have a zeta potential ranging between ⁇ 10 mV to +10 mV.
  • the AE nanoparticles are micelles. In some embodiments, the AE nanoparticles provided in accordance with the present invention are nanospheres. In some embodiments, the AE nanoparticles comprise one or more amphiphilic entities. Inventive AE nanoparticles may optionally comprise one or more dispersion media, surfactants, biologically active agents, or release-retarding ingredients.
  • compositions may be emulsions or dispersions.
  • the compositions are “oil-in-water” dispersions (i.e., dispersions in which oily particles are dispersed within an aqueous dispersion medium); in some embodiments, the compositions are “water-in-oil” dispersions (i.e., dispersions in which aqueous particles are dispersed within an oily dispersion medium).
  • some or all of the nanoparticles have a micellar structure in which a lumen is enclosed by a micellar “membrane.” In some such embodiments, the lumen of the micelle has the same character (e.g., aqueous vs.
  • the lumen of the micelle has the same character as the micellar membrane and the dispersion medium has the opposing character.
  • the invention provides methods of preparing the inventive AE nanoparticles.
  • the method generally involves combining one or more amphiphilic entities to form a “premix” and applying high shear forces to the premix.
  • the premix generally contains one or more amphiphilic entities and one or more dispersion media.
  • the premix may also contain one or more additional substances such as, for example, surfactants, biologically active agents, release-retarding ingredients, etc.
  • additional substances such as, for example, surfactants, biologically active agents, release-retarding ingredients, etc.
  • the premix components are selected and/or maintained under conditions that permit nanoparticle formation before the high shear forces are applied. In some embodiments, the premix is not maintained under conditions that permit particle formation before the high shear forces are applied. In some embodiments, these particles are nano- or micro-particles. In some embodiments, these particles are micelles. In some embodiments, nanoparticles are allowed to form from the premix components before the high shear forces are applied. In some embodiments, nanoparticle formation in the premix is inhibited before the high shear forces are applied. In certain embodiments, the high shear forces are applied after nanoparticles have formed from the premix components. In certain embodiments, the high shear forces are applied before nanoparticles form from the premix components. In certain embodiments, the high shear forces are applied while nanoparticles are forming from the premix components.
  • the present invention provides methods of manufacturing AE nanoparticles.
  • the method generally involves preparing a premix of two or more amphiphilic entities and subjecting the premix to high shear forces.
  • the premix may comprise one or more dispersion media, surfactants, biologically active agents, or release-retarding ingredients.
  • the methods of producing inventive AE nanoparticles involve steps of providing a premix, allowing or inducing assembly of particles (e.g., nanoparticles, microparticles, and/or micelles) within the premix, and subjecting the particles to high shear forces such that an inventive nanoparticle composition is obtained.
  • particle formation in the premix may be by emulsion polymerization, self-assembly, or by any other known technique for producing micro- or nano-particles.
  • particle formation in the premix may involve the steps of dissolving an amphiphilic entity in a dispersion medium, gradually adding water to the solution of dispersion medium and amphiphilic entity, and waiting for particles (e.g. nanoparticles, microparticles, and/or micelles) to self-assemble.
  • particle formation can be induced by slowly cooling the solution.
  • particle formation in the premix may involve the steps of dissolving an amphiphilic entity in a dispersion medium such as water, stirring for 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 hours while allowing particles (e.g. nanoparticles, microparticles, and/or micelles) to form, dialyzing against water to remove any organic dispersion medium to stabilize the particles, and freeze-drying to produce a composition.
  • a dispersion medium such as water
  • particles e.g. nanoparticles, microparticles, and/or micelles
  • the premix components may assemble into particles before the application of high shear force. At least some of such particles may be microparticles or even nanoparticles.
  • an inventive nanoparticle composition is prepared from a premix, wherein the premix is selected from the group comprising a suspension or a microemulsion. In some embodiments, however, particle structures do not form in the premix before application of high shear force.
  • all of the components present in the final nanoparticle composition are present in the premix and are subjected to high shear force to produce the nanoparticle composition.
  • one or more of the components that are present in the final nanoparticle composition is/are missing from the premix or is/are present in the premix in a smaller amount than in the final nanoparticle composition. That is, in some embodiments of the present invention, one or more materials are added to the nanoparticle composition after the premix is subjected to high shear stress.
  • the premix is prepared as a solution prior to application of high shear force.
  • at least one biologically active agent e.g., an unmodified peptide
  • the biologically active agent is soluble in at least one of the media (or in a combination of media utilized in the premix). In some embodiments of the invention, such dissolution requires heating; in other embodiments it does not.
  • amphiphilic entities include natural entities, synthetic entities, and entities that contain both natural and synthetic components.
  • amphiphilic entities may comprise one or more polymers, and/or one or more compounds with polymeric character.
  • an amphiphilic entity is one that has both hydrophobic and hydrophilic natures.
  • an amphiphilic entity can be comprised in any number of different ways.
  • an amphiphilic entity may comprise one or more individual compounds or substances that is itself amphiphilic.
  • such compounds or molecules include polyethylene glycol (PEG), phospholipids, cholesterols, glycolipids fatty acids, bile acids, and saponins
  • PEG is generally recognized as safe for use in food, cosmetics, and medicines by the US Food and Drug Administration.
  • PEG is water-soluble, non-toxic, odorless, lubricating, nonvolatile, and nonirritating.
  • an amphiphilic entity may comprise one or more individual components that is not itself amphiphilic but that has some hydrophilic or hydrophobic character.
  • two or more such non-amphiphilic components will typically be associated with one another such that the assemblage of the individual components is amphiphilic.
  • association may or may not involve covalent linkage; such association may involve non-covalent bonding (e.g., via electrostatic interactions, affinity interactions, hydrophobic interactions, hydrogen bonding, Van der Waals interactions, ionic interaction, dipole-dipole interaction, etc.). In general, such association may involve any relevant force, bond, or means of adhesion.
  • an amphiphilic entity of the present invention may be constructed from two or more individual components having differing degrees of hydrophilicity or hydrophobicity.
  • an amphiphilic entity may comprise at least one hydrophilic component and at least one hydrophobic component.
  • the “hydrophilic” and “hydrophobic” components are either hydrophilic or hydrophobic relative to one another.
  • two or more components of differing degrees of hydrophilicity or hydrophobicity may be bonded together by covalent bonds to form a homopolymer or a co-polymer.
  • a co-polymer may be a block co-polymer.
  • a co-polymer may be a graft co-polymer.
  • an amphiphilic entity may comprise or consist of an amphiphilic block co-polymer.
  • an amphiphilic block co-polymer may be a diblock co-polymer.
  • an amphiphilic diblock co-polymer may comprise a first polymer block and a second polymer block connected covalently at the chain ends.
  • the first polymer block may comprise repeating units of a hydrophilic component
  • the second polymer block may comprise repeating units of a hydrophobic component.
  • the first polymer block may comprise repeating units of a hydrophobic component
  • the second polymer block may comprise repeating units of a hydrophilic component.
  • an amphiphilic block co-polymer may be a multiblock co-polymer.
  • an amphiphilic block co-polymer may comprise multiple alternating blocks of two or more polymers connected covalently at the chain ends.
  • an amphiphilic block co-polymer may comprise multiple alternating hydrophilic blocks and hydrophobic blocks connected covalently at the chain ends.
  • each block of the alternating blocks may comprise repeating units of either hydrophilic components or hydrophobic components.
  • an amphiphilic entity may comprise or consist of an amphiphilic graft co-polymer.
  • an amphiphilic graft co-polymer may comprise or consist of blocks of polymers connected covalently to the side chains of other blocks of polymers.
  • each polymer block may comprise or consist of repeating units of either hydrophilic or hydrophobic components.
  • an amphiphilic graft co-polymer may comprise or consist of a first polymer block and a second polymer block connected covalently to a side chain of the first polymer block.
  • the first polymer block may comprise or consist of repeating units of a hydrophilic component
  • the second block may comprise repeating units of a hydrophobic component.
  • the first polymer block may comprise or consist of repeating units of a hydrophobic component
  • the second block may comprise repeating units of a hydrophilic component.
  • an amphiphilic block or graft co-polymer may include a hydrophilic polymer block comprising repeating units of a polysaccharide and a hydrophobic polymer block comprising repeating units of a polyester or polysaccharide.
  • an amphiphilic block or graft co-polymer may include a hydrophobic polymer block comprising repeating units of a polysaccharide and a hydrophilic polymer block comprising repeating units of a polyester or polysaccharide.
  • Such a hydrophilic polymer block can contain repeating units of any type of hydrophilic polymer, such as a polysaccharide (e.g. pullulan) or polyalkene oxide (e.g.
  • the hydrophobic polymer block can contain repeating units of any type of hydrophobic polymer, such as a polycaprolactone, poly (lactic acid), poly (glycolic acid), poly dioxanone, copolymers of these or polyamide (e.g. polycaprolactam).
  • a polycaprolactone poly (lactic acid), poly (glycolic acid), poly dioxanone, copolymers of these or polyamide (e.g. polycaprolactam).
  • the hydrophilic portion of the amphiphilic entity may be non-ionic.
  • the hydrophilic component of an amphiphilic entity comprises one or more ionic groups. In general, such ionic groups are hydrophilic and can confer hydrophilic nature on the amphiphilic entity.
  • the ionic group may be cationic.
  • the cationic group may be an ammonium (NH 4 + ), nitronium (NO 2 + ), nitrosyl (NO + ), hydronium (H 3 O + ), mercurous (Hg 2 2+ ), phosphonium (PH 4 + ), vanadyl (VO 2+ ), or salt thereof.
  • the ionic group may be anionic.
  • the anionic group may be a fatty acid, arsenide (As 3 ⁇ ), azide (N 3 ⁇ ), bromide (Br ⁇ ), chloride (Cl ⁇ ), fluoride (F ⁇ ), hydride (H ⁇ ), iodide (I ⁇ ), nitride (N 3 ⁇ ), oxide (O 2 ⁇ ), phosphide (P 3 ⁇ ), selenide (Se 2 ⁇ ), sulfide (S 2 ⁇ ), peroxide (O 2 2 ⁇ ), arsenate (AsO 4 3 ⁇ ), arsenite (AsO 3 3 ⁇ ), borate (BO 3 3 ⁇ ), perbromate (BrO 4 ⁇ ), bromate (BrO 3 ⁇ ), bromite (BrO 2 ⁇ ), hypobromite (BrO ⁇ ), carbonate (CO 3 2 ⁇ ), hydrogen carbonate (As 3 ⁇ ), ar
  • the hydrophilic component of an amphiphilic entity may comprise or consist of a nucleic acid.
  • the nucleic acid polymer may include DNA, RNA, or combinations thereof.
  • the nucleic acid polymer may be an oligonucleotide and/or polynucleotide.
  • the nucleic acid polymer may be an oligonucleotide and/or modified oligonucleotide; an antisense oligonucleotide and/or modified antisense oligonucleotide; a cDNA; a genomic DNA; viral DNA and/or RNA; DNA and/or RNA chimeras; plasmids; cosmids; gene fragments; an artificial and/or natural chromosome (e.g. a yeast artificial chromosome) and/or a part thereof; an RNA (e.g.
  • RNA an mRNA, a tRNA, an rRNA and/or a ribozyme
  • PNA peptide nucleic acid
  • a polynucleotide comprising synthetic analogues of nucleic acids, which may be modified or unmodified
  • various structural forms of DNA including single-stranded DNA, double-stranded DNA, supercoiled DNA and/or triple-helical DNA; Z-DNA; and/or combinations thereof.
  • the hydrophilic component of an amphiphilic entity may comprise or consist of a carbohydrate.
  • the carbohydrate may be a polysaccharide composed of simple sugars (or their derivatives) connected by glycosidic bonds, as known in the art.
  • sugars may include, but are not limited to, glucose, fructose, galactose, ribose, lactose, sucrose, maltose, trehalose, cellbiose, mannose, xylose, arabinose, glucoronic acid, galactoronic acid, mannuronic acid, glucosamine, galatosamine, and neuramic acid.
  • the polymer may be a hydrophilic carbohydrate, including aminated, carboxylated, and sulfated polysaccharides.
  • the hydrophilic carbohydrate may be one or more of pullulan, cellulose, microcrystalline cellulose, hydroxypropyl methylcellulose, hydroxycellulose, methylcellulose, dextran, cyclodextran, glycogen, starch, hydroxyethylstarch, carageenan, glycon, amylose, chitosan, N,O-carboxylmethylchitosan, algin and alginic acid, starch, chitin, heparin, konjac, glucommannan, pustulan, heparin, hyaluronic acid, curdlan, and xanthan.
  • hydrophilic polysaccharides can be modified to become hydrophobic by introducing a large number of side-chain hydrophobic groups.
  • a hydrophobic carbohydrate may include cellulose acetate, pullulan acetate, konjac acetate, amylose acetate, and dextran acetate.
  • the hydrophilic component of an amphiphilic entity may comprise or consist of a gum including, but not limited to, xanthan gum, alginic acid, caraya gum, sodium alginate, and/or locust bean gum.
  • a component of an amphiphilic entity may comprise or consist of a protein.
  • a protein is a hydrophilic component of an amphiphilic entity.
  • a protein is a hydrophobic component of an amphiphilic entity.
  • Exemplary proteins that may be used in accordance with the present invention include, but are not limited to, albumin, collagen, or a poly(amino acid) (e.g. polylysine).
  • the hydrophobic component of an amphiphilic entity may comprise or consist of one or more fatty acid groups or salts thereof. In general, such groups are typically hydrophobic and can confer hydrophobic nature onto the amphiphilic entity.
  • the fatty acid group may comprise digestible, long chain (e.g., C 8 -C 50 ), substituted or unsubstituted hydrocarbons.
  • the fatty acid group may be a C 10 -C 20 fatty acid or salt thereof.
  • the fatty acid group may be a C 15 -C 20 fatty acid or salt thereof.
  • the fatty acid group may be a C 15 -C 25 fatty acid or salt thereof.
  • the fatty acid group may be unsaturated. In some embodiments, the fatty acid group may be monounsaturated. In some embodiments, the fatty acid group may be polyunsaturated. In some embodiments, a double bond of an unsaturated fatty acid group may be in the cis conformation. In some embodiments, a double bond of an unsaturated fatty acid may be in the trans conformation.
  • the fatty acid group may be one or more of butyric, caproic, caprylic, capric, lauric, myristic, palmitic, stearic, arachidic, behenic, or lignoceric acid.
  • the fatty acid group may be one or more of palmitoleic, oleic, vaccenic, linoleic, alpha-linoleic, gamma-linoleic, arachidonic, gadoleic, arachidonic, eicosapentaenoic, docosahexaenoic, or erucic acid.
  • the hydrophobic component of an amphiphilic entity may comprise or consist of one or more biocompatible and/or biodegradable synthetic polymers, including, for example, polyethylenes, polycarbonates (e.g. poly(1,3-dioxan-2one)), polyanhydrides (e.g. poly(sebacic anhydride)), polyhydroxyacids (e.g. poly( ⁇ -hydroxyalkanoate)), polypropylfumerates, polycaprolactones, polyamides (e.g. polycaprolactam), polyacetals, polyethers, polyesters (e.g.
  • biocompatible and/or biodegradable synthetic polymers including, for example, polyethylenes, polycarbonates (e.g. poly(1,3-dioxan-2one)), polyanhydrides (e.g. poly(sebacic anhydride)), polyhydroxyacids (e.g. poly( ⁇ -hydroxyalkanoate)), polypropylfumerates, polycaprolactones, poly
  • the amphiphilic entity may comprise one or more of the following biodegradable polymers: poly(lactic acid), poly(glycolic acid), poly(caprolactone), poly(lactide-co-glycolide), poly(lactide-co-caprolactone), poly(glycolide-co-caprolactone), and poly(DL-lactide-co-glycolide).
  • the hydrophobic component of an amphiphilic entity may comprise or consist of one or more acrylic polymers.
  • acrylic polymers include, for example, acrylic acid and methacrylic acid copolymers, methyl methacrylate copolymers, ethoxyethyl methacrylates, cyanoethyl methacrylate, aminoalkyl methacrylate copolymer, poly(acrylic acid), poly(methacrylic acid), methacrylic acid alkylamide copolymer, poly(methyl methacrylate), poly(methacrylic acid anhydride), methyl methacrylate, polymethacrylate, poly(methyl methacrylate) copolymer, polyacrylamide, aminoalkyl methacrylate copolymer, glycidyl methacrylate copolymers, and combinations comprising one or more of the foregoing polymers.
  • the acrylic polymer may comprise fully-polymerized copolymers of acrylic and methacrylic acid esters with a low content
  • the hydrophobic component of an amphiphilic entity may comprise or consist of a polyester.
  • polyesters include, for example, polyalkylene glycols, poly(glycolide-co-lactide), PEGylated poly(lactic-co-glycolic acid), poly(lactic acid), PEGylated poly(lactic acid), poly(glycolic acid), PEGylated poly(glycolic acid), co-polymers of polylactic and polyglycolic acid, and derivatives thereof.
  • polyesters include, for example, polyanhydrides, poly(ortho ester) PEGylated poly(ortho ester), poly(caprolactone), PEGylated poly(caprolactone), polylysine, PEGylated polylysine, poly(ethylene imine), PEGylated poly(ethylene imine), and derivatives thereof.
  • polyesters may include, for example, polycaprolactone, poly(L-lactide-co-L-lysine), poly(serine ester), poly(4-hydroxy-L-proline ester), poly[ ⁇ -(4-aminobutyl)-L-glycolic acid], and derivatives thereof.
  • amphiphilic entities may have biological activity.
  • the percent of amphiphilic entity in the composition from which AE nanoparticles are prepared can range from 40% to 99%, from 50% to 99%, from 60% to 99%, from 70% to 99%, from 80% to 99%, from 80% to 90%, or from 90% to 99%.
  • the percent of amphiphilic entity in the composition from which AE nanoparticles are prepared is approximately 75%, approximately 76%, approximately 77%, approximately 78%, approximately 79%, approximately 80%, approximately 81%, approximately 82%, approximately 83%, approximately 84%, approximately 85%, approximately 86%, approximately 87%, approximately 88%, approximately 89%, approximately 90%, approximately 91%, approximately 92%, approximately 93%, approximately 94%, approximately 95%, approximately 96%, approximately 97%, approximately 98%, or approximately 99%.
  • the premix is expected to contain at least one dispersion medium.
  • the premix may contain a hydrophilic dispersion medium.
  • the premix may contain a hydrophobic dispersion medium.
  • the premix may contain a combination of two or more dispersion media, for example of different characters.
  • the premix may contain at least two immiscible dispersion media.
  • the selection of appropriate dispersion medium will depend, at least in part, on the nature of the amphiphilic entit(ies) being employed and on whether it is intended for the intended external and internal character of the intended nanoparticles.
  • the nanoparticles will have hydrophilic external character and hydrophobic internal character; in some embodiments, the nanoparticles will have hydrophobic external character and hydrophilic character; in some embodiments, the nanoparticles will have hydrophilic external and internal character; and in some embodiments, the nanoparticles with have hydrophobic external and internal character.
  • the same nanoparticle components can sometimes assemble into different nanoparticle structures, having different internal and external characters.
  • nanoparticles formed from a monolayer of an individual amphiphilic compound will have differing external and internal characters
  • nanoparticles formed from a bilayer of the same compound will have the same external and internal character.
  • hydrophilic dispersion media are utilized.
  • such hydrophilic dispersion media are aqueous.
  • aqueous dispersion media include but are not limited to, water, short chain alcohols (e.g. ethanol), oils, 5% dextrose, Ringer's solutions (e.g.
  • lactated Ringer's injection lactated Ringer's plus 5% dextrose injection, aceylated Ringer's injection
  • Normosol-M Isolyte E, dimethyl sulfoxide (DMSO), dimethyl acetamide, dimethyl formamide, chloroform, tetramethyl formamide, carbon tetrachloride, N-methylpyrolidone, or dichloroethane, and the like, and combinations thereof.
  • hydrophobic dispersion media are utilized.
  • such hydrophobic dispersion media are oils.
  • the oil may comprise one or more fatty acid groups or salts thereof.
  • the fatty acid group may comprise digestible, long chain (e.g., C 8 -C 50 ), substituted or unsubstituted hydrocarbons.
  • the fatty acid group may be a C 10 -C 20 fatty acid or salt thereof.
  • the fatty acid group may be a C 15 -C 20 fatty acid or salt thereof.
  • the fatty acid group may be a C 15 -C 25 fatty acid or salt thereof. In some embodiments, the fatty acid group may be unsaturated. In some embodiments, the fatty acid group may be monounsaturated. In some embodiments, the fatty acid group may be polyunsaturated. In some embodiments, a double bond of an unsaturated fatty acid group may be in the cis conformation. In some embodiments, a double bond of an unsaturated fatty acid may be in the trans conformation.
  • the fatty acid group may be one or more of butyric, caproic, caprylic, capric, lauric, myristic, palmitic, stearic, arachidic, behenic, or lignoceric acid.
  • the fatty acid group may be one or more of palmitoleic, oleic, vaccenic, linoleic, alpha-linolenic, gamma-linoleic, arachidonic, gadoleic, arachidonic, eicosapentaenoic, docosahexaenoic, or erucic acid.
  • the oil is a liquid triglyceride.
  • the oil is a medium chain (e.g., 6-12 carbons) triglyceride (e.g., Labrafac WL 1349, coconut oil, palm kernel oil, camphor tree drupe oil, etc.).
  • the oil is a short chain (e.g., 2-5 carbons) triglyceride.
  • the oil is a long chain (e.g., greater than 12 carbons) triglyceride (e.g., soybean oil, sunflower oil, etc.).
  • Suitable oils for use with the present invention include, but are not limited to, almond, apricot kernel, avocado, babassu, bergamot, black current seed, borage, cade, chamomile, canola, caraway, carnauba, castor, cinnamon, cocoa butter, coconut, cod liver, coffee, corn, cotton seed, emu, eucalyptus, evening primrose, fish, flaxseed, geraniol, gourd, grape seed, hazel nut, hyssop, jojoba, kukui nut, lavandin, lavender, lemon, litsea cubeba, macadamia nut, mallow, mango seed, meadowfoam seed, mink, nutmeg, olive, orange, orange roughy, palm, palm kernel, peach kernel, peanut, poppy seed, pumpkin seed, rapeseed, rice bran, rosemary, safflower, sandalwood, sasquana, savoury,
  • Suitable oils for use with the present invention include, but are not limited to, butyl stearate, caprylic triglyceride, capric triglyceride, cyclomethicone, diethyl sebacate, dimethicone 360, isopropyl myristate, mineral oil, octyldodecanol, oleyl alcohol, silicone oil, and combinations thereof.
  • the term “dispersion medium” is not intended to imply a particular amount of the material be present.
  • the relative amounts of different dispersion media may be adjusted as desired.
  • the percent of dispersion medium in the composition from which AE nanoparticles are prepared can range from 0% to 99%, from 10% to 99%, from 25% to 99%, from 50% to 99%, or from 75% to 99%.
  • the percent of dispersion medium in the composition from which AE nanoparticles are prepared can range from 0% to 75%, from 0% to 50%, from 0% to 25%, or from 0% to 10%.
  • the percent of oil in the composition from which AE nanoparticles are prepared ranges between 0% to 30%. In some embodiments the percent of oil in the composition from which AE nanoparticles are prepared (e.g., in the premix) is approximately 1%, approximately 2%, approximately 3%, approximately 4%, approximately 5%, approximately 6%, approximately 7%, approximately 9%, approximately 10%, approximately 11%, approximately 12%, approximately 13%, approximately 14%, approximately 15%, approximately 16%, approximately 17%, approximately 18%, approximately 19%, approximately 20%, approximately 21%, approximately 22%, approximately 23%, approximately 24%, approximately 25%, approximately 26%, approximately 27%, approximately 28%, approximately 29%, or approximately 30%. In some embodiments the percent of oil is approximately 8%. In some embodiments the percent of oil is approximately 5%.
  • the premix comprises oil and surfactant at a ratio ranging between 0.5:1 to 10:1.
  • the ratio of oil to surfactant is approximately 0.5:1, approximately 1:1, approximately 2:1, approximately 3:1, approximately 4:1, approximately 5:1, approximately 6:1, approximately 7:1, approximately 8:1, approximately 9:1, or approximately 10:1.
  • the ratio of surfactant to oil is approximately 0.5:1, approximately 1:1, approximately 2:1, approximately 3:1, approximately 4:1, approximately 5:1, approximately 6:1, approximately 7:1, approximately 8:1, approximately 9:1, or approximately 10:1.
  • the premix comprises oil and surfactant at a ratio ranging between 0.5:1 to 2:1.
  • the ratio of oil to surfactant is approximately 0.5:1, approximately 1:1, or approximately 2:1. In some embodiments, the ratio of surfactant to oil is approximately 0.5:1, approximately 1:1, or approximately 2:1. In certain embodiments, the ratio of oil to surfactant is approximately 1:1.
  • the premix may optionally comprise one or more substances with surfactant activity.
  • a substance with surfactant activity can promote the production of AE nanoparticles with increased stability, improved uniformity, or increased viscosity.
  • Surfactants can be particularly useful in embodiments that utilize two or more dispersion media.
  • the percent of substances with surfactant activity in the composition from which AE nanoparticles are prepared can range from 0% to 99%, from 10% to 99%, from 25% to 99%, from 50% to 99%, or from 75% to 99%.
  • the percent of substances with surfactant activity in the composition from which AE nanoparticles are prepared can range from 0% to 75%, from 0% to 50%, from 0% to 25%, or from 0% to 10%.
  • the percent of substances with surfactant activity in the composition from which AE nanoparticles are prepared ranges between 0% to 30%. In some embodiments the percent of substances with surfactant activity in the composition from which AE nanoparticles are prepared (e.g., in the premix) is approximately 1%, approximately 2%, approximately 3%, approximately 4%, approximately 5%, approximately 6%, approximately 7%, approximately 9%, approximately 10%, approximately 11%, approximately 12%, approximately 13%, approximately 14%, approximately 15%, approximately 16%, approximately 17%, approximately 18%, approximately 19%, approximately 20%, approximately 21%, approximately 22%, approximately 23%, approximately 24%, approximately 25%, approximately 26%, approximately 27%, approximately 28%, approximately 29%, or approximately 30%. In some embodiments the percent of substances with surfactant activity is approximately 8%. In some embodiments the percent of substances with surfactant activity is approximately 5%.
  • surfactants include, but are not limited to, phosphoglycerides; phosphatidylcholines; dipalmitoyl phosphatidylcholine (DPPC); dioleylphosphatidyl ethanolamine (DOPE); dioleyloxypropyltriethylammonium (DOTMA); dioleoylphosphatidylcholine; cholesterol; cholesterol ester; diacylglycerol; diacylglycerolsuccinate; diphosphatidyl glycerol (DPPG); hexanedecanol; fatty alcohols such as polyethylene glycol (PEG); polyoxyethylene-9-lauryl ether; a surface active fatty acid, such as palmitic acid or oleic acid; fatty acids; fatty acid monoglycerides; fatty acid diglycerides; fatty acid amides; sorbitan trioleate (Span
  • Inventive AE nanoparticle compositions may be utilized to deliver one or more biologically active agents.
  • biologically active agents may be delivered in conjunction with inventive AE nanoparticles.
  • the biologically active agent is included in the premix.
  • the biologically active agent is added after AE nanoparticle formation.
  • Any biologically active agents including, for example, therapeutic, diagnostic, prophylactic, nutritional, cosmetic, and/or dermatological agents, may be delivered according to the present invention.
  • Such biologically active agents may be small molecules, organometallic compounds, nucleic acids, proteins (including multimeric proteins, protein complexes, etc.), peptides, lipids, carbohydrates, herbs, hormones, metals, radioactive elements and compounds, drugs, vaccines, immunological agents, etc., and/or combinations thereof.
  • Such biologically agents may be encapsulated within, adsorbed to the surface of, and/or present within the micellar membrane of inventive AE nanoparticles.
  • the percent of biologically active agent in the premix or in nanoparticles ranges from 0.1% to 25%. In some embodiments, the percentage of biologically active agent in the premix or in nanoparticles ranges from 0.1% to 20%, from 0.1% to 15%, from 0.1% to 10%, from 0.1% to 5%, or from 0.1% to 1%. In some embodiments, the percentage of biologically active agent in the premix or in nanoparticles ranges from 1% to 20%, from 5% to 20%, from 10% to 20%, from 15% to 20%, or from 15% to 25%. In some embodiments, the percentage of biologically active agent in the premix or in nanoparticles is less than 0.1%.
  • the percentage of biologically active agent in the premix or in nanoparticles is greater than 25%. In some embodiments, the percentage of biologically active agent in the premix or in nanoparticles is approximately 0.1%, approximately 1%, approximately 2%, approximately 3%, approximately 4%, approximately 5%, approximately 6%, approximately 7%, approximately 8%, approximately 9%, approximately 10%, approximately 11%, approximately 12%, approximately 13%, approximately 14%, approximately 15%, approximately 16%, approximately 17%, approximately 18%, approximately 19%, approximately 20%, approximately 21%, approximately 22%, approximately 23%, approximately 24%, approximately 25%, or greater.
  • biologically active agents can be produced or obtained according to any available method or approach.
  • Biologically active agents may contain, or be modified to contain, one or more moieties intended to facilitate their use or delivery in conjunction with inventive nanoparticles. Such modification should not interfere with the biological activity of the agent.
  • the modification can optionally be removed in vivo.
  • biologically active agents may be detectably labeled and/or may be provided in a “pro” form that is converted or modified after delivery into an active form.
  • the biologically active agent is a small molecule and/or organic compound with pharmaceutical activity.
  • the biologically active agent is a clinically-used drug.
  • the drug is an antibiotic, anti-viral agent, anesthetic, anticoagulant, anti-cancer agent, inhibitor of an enzyme, steroidal agent, anti-inflammatory agent, anti-neoplastic agent, antigen, vaccine, antibody, decongestant, antihypertensive, sedative, birth control agent, progestational agent, anti-cholinergic, analgesic, anti-depressant, anti-psychotic, ⁇ -adrenergic blocking agent, diuretic, cardiovascular active agent, vasoactive agent, non-steroidal anti-inflammatory agent, etc.
  • the biologically active agents delivered may be a mixture of pharmaceutically active agents.
  • a local anesthetic may be delivered in combination with an anti-inflammatory agent such as a steroid.
  • Local anesthetics may also be administered with vasoactive agents such as epinephrine.
  • an antibiotic may be combined with an inhibitor of the enzyme commonly produced by bacteria to inactivate the antibiotic (e.g., penicillin and clavulanic acid).
  • the biologically active agent is a diagnostic agent.
  • diagnostic agents include gases; commercially available imaging agents used in positron emissions tomography (PET), computer assisted tomography (CAT), single photon emission computerized tomography, x-ray, fluoroscopy, and magnetic resonance imaging (MRI); and contrast agents.
  • PET positron emissions tomography
  • CAT computer assisted tomography
  • MRI magnetic resonance imaging
  • contrast agents include gadolinium chelates, as well as iron, magnesium, manganese, copper, and chromium.
  • materials useful for CAT and x-ray imaging include iodine-based materials.
  • the biologically active agent is a prophylactic agent.
  • prophylactic agents include vaccines.
  • Vaccines may comprise isolated proteins or peptides, inactivated organisms and viruses, dead organisms and virus, genetically altered organisms or viruses, and cell extracts.
  • Prophylactic agents may be combined with interleukins, interferon, cytokines, and adjuvants such as cholera toxin, alum, Freund's adjuvant, etc.
  • Prophylactic agents may include antigens of such bacterial organisms as Streptococccus pnuemoniae, Haemophilus influenzae, Staphylococcus aureus, Streptococcus pyrogenes, Corynebacterium diphtheriae, Listeria monocytogenes, Bacillus anthracis, Clostridium tetani, Clostridium botulinum, Clostridium perfringens, Neisseria meningitidis, Neisseria gonorrhoeae, Streptococcus mutans, Pseudomonas aeruginosa, Salmonella typhi, Haemophilus parainfluenzae, Bordetella pertussis, Francisella tularensis, Yersinia pestis, Vibrio cholerae, Legionella pneumophila, Mycobacterium tuberculosis, Mycobacterium leprae, Treponema
  • the biologically active agent may be a protein.
  • protein and “peptide” can be used interchangeably.
  • peptides range from about 5 to 40, 10 to 35, 15 to 30, or 20 to 25 amino acids in size. Peptides from panels of peptides comprising random sequences and/or sequences which have been varied consistently to provide a maximally diverse panel of peptides may be used.
  • the biologically active agent may be an antibody.
  • antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric (i.e. “humanized”), single chain (recombinant) antibodies.
  • antibodies may have reduced effector functions and/or bispecific molecules.
  • antibodies may include Fab fragments and/or fragments produced by a Fab expression library.
  • the biologically active agent may be a nucleic acid.
  • the oligonucleotides comprise DNA, RNA, chimeric mixtures, derivatives, characteristic portions, and/or modified versions thereof.
  • the oligonucleotides of the present invention may be single-stranded and/or double-stranded.
  • the oligonucleotide may be modified at the base moiety, sugar moiety, and/or phosphate backbone, for example, to improve stability of the molecule, hybridization, etc.
  • a nucleic acid comprises an antisense molecule that binds to a translational start site, transcriptional start site, and/or splice junctions.
  • Antisense oligonucleotides will bind to a target mRNA and/or prevent translation.
  • the antisense oligonucleotide may bind to DNA of a target gene, such as, for example, a regulatory element.
  • a nucleic acid comprises a ribozyme designed to catalytically cleave target mRNA transcripts may be used to prevent translation of a target mRNA and/or expression of a target (see, e.g., PCT publication WO 90/11364; and Sarver et al., 1990 , Science 247:1222; both of which are incorporated herein by reference).
  • endogenous target gene expression may be reduced by targeting deoxyribonucleotide sequences complementary to the regulatory region of the target gene (i.e., the target gene's promoter and/or enhancers) to form triple helical structures that prevent transcription of the target gene in target muscle cells in the body (see generally, Helene, 1991 , Anticancer Drug Des. 6:569; Helene et al., 1992 , Ann, N.Y. Acad. Sci. 660:27; and Maher, 1992 , Bioassays 14:807; all of which are incorporated herein by reference).
  • deoxyribonucleotide sequences complementary to the regulatory region of the target gene i.e., the target gene's promoter and/or enhancers
  • the biologically active agent is a nutraceutical agent.
  • the nutraceutical agent provides basic nutritional value.
  • the nutraceutical agent provides health or medical benefits.
  • the nutraceutical agent is a dietary supplement.
  • the nutraceutical agent is a vitamin.
  • the vitamin is one or more of vitamin A (retinoids), vitamin B1 (thiamine), vitamin B2 (riboflavin), vitamin B3 (niacin), vitamin B5 (pantothenic acid), vitamin B6 (pyroxidone), vitamin B7 (biotin), vitamin B9 (folic acid), vitamin B12 (cyanocobalamin), vitamin C (ascorbic acid), vitamin D, vitamin E, or vitamin K.
  • the nutraceutical agent is a mineral.
  • the mineral is one or more of bismuth, boron, calcium, chlorine, chromium, cobalt, copper, fluorine, iodine, iron, magnesium, manganese, molybdenum, nickel, phosphorus, potassium, rubidium, selenium, silicon, sodium, strontium, sulfur, tellurium, titanium, tungsten, vanadium, or zinc.
  • the nutraceutical agent is an essential amino acid.
  • the amino acid is one or more of arginine, glutamine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, or valine.
  • nutraceutical agents may include fatty acids and/or omega-3 fatty acids (e.g. DHA or ARA), fruit and vegetable extracts, lutein, phosphatidylserine, lipoid acid, melatonin, glucosamine, chondroitin, aloe vera, guggul, green tea, lycopene, whole foods, food additives, herbs, phytonutrients, antioxidants, flavonoid constituents of fruits, evening primrose oil, flaxseeds, fish and marine animal oils (e.g. cod liver oil), and probiotics.
  • nutraceutical agents may include bio-engineered foods genetically-engineered to have a desired property (also known as “pharmafoods”).
  • nutraceutical agents and dietary supplements are disclosed, for example, in Roberts et al., ( Nutriceuticals: The Complete Encyclopedia of Supplements, Herbs, Vitamins, and healing Foods , American Nutriceutical Association, 2001; incorporated herein by reference). Nutraceutical agents and dietary supplements are also disclosed in Physicians' Desk Reference for Nutritional Supplements, 1st Ed., 2001 and Physicians' Desk Reference for Herbal Medicines, 1st Ed., 2001 (incorporated herein by reference).
  • AE nanoparticles loaded with nutraceutical agents can be incorporated into food substances.
  • the nutraceutical-loaded AE nanoparticles can be dissolved into liquids, such as beverages.
  • the biologically active agent is a cosmetic and/or dermatological agent.
  • the cosmetic and/or dermatological agent may optionally include excipients such as sequestering agents, softeners, coloring materials (e.g. pigments and dyes), and fragrances.
  • the cosmetic and/or dermatological agent may be a composition including, but not limited to, skin softener, nutrition lotion, cleansing lotion, cleansing cream, skin milk, emollient lotion, massage cream, emollient cream, make-up base, lipstick, facial pack or facial gel, cleaner formulation (e.g. shampoos, rinses, body cleanser, hair-tonics, and soaps), and dermatological composition (e.g. lotions, ointments, gels, creams, patches and sprays).
  • the cosmetic and/or dermatological agent may include vitamins and their derivatives (e.g. vitamin E and its esters, vitamin C and its esters, vitamins B, vitamin A alcohol or retinol and its esters), provitamins (e.g. panthenol, niacinamide or ergocalciferol), antioxidants, phenolic compounds (e.g. benzoyl peroxide), essential oils, humectants, sunscreen agents, moisturizing agents, proteins, ceramides, and pseudoceramides.
  • vitamins and their derivatives e.g. vitamin E and its esters, vitamin C and its esters, vitamins B, vitamin A alcohol or retinol and its esters
  • provitamins e.g. panthenol, niacinamide or ergocalciferol
  • antioxidants e.g. benzoyl peroxide
  • phenolic compounds e.g. benzoyl peroxide
  • sunscreen agents moisturizing agents, proteins, ceramides
  • the biologically active agent may be one or more botulinum toxin peptides or protein complexes.
  • the botulinum toxin may be one or more of botulinum toxin serotypes A, B, C 1 , C 2 , D, E, F, or G.
  • the botulinum toxin may be an isolated and/or purified botulinum toxin.
  • the botulinum toxin may be a partially-isolated and/or partially-purified botulinum toxin.
  • the botulinum toxin may be a native botulinum complex.
  • the botulinum toxin may be associated with non-toxin proteins.
  • the botulinum toxin may be a recombinantly-made botulinum toxin.
  • Any biologically active agent may be encapsulated within or bound to the surface of AE nanoparticles.
  • AE nanoparticles comprising a biologically active agent may optionally include one or more release-retarding ingredients to allow for controlled release of the agent.
  • Any release-retarding ingredient known in the art is suitable for use in making the inventive AE nanoparticles.
  • release-retarding ingredients are hydrophilic and/or hydrophobic polymers. Release-retarding ingredients include, for example celluloses or derivatives thereof, acrylic polymers, ester polymers, vinyl-pyrrolidone-based polymers, gums, other natural polymers, and/or combinations of these.
  • the release-retarding ingredient is cellulose or a derivative thereof.
  • the cellulose or derivative thereof comprises one or more of hydroxypropyl methylcellulose, methylcellulose, carboxymethylcellulose, sodium carboxymethylcellulose, hydroxypropyl ethylcellulose, hydroxyethylcellulose, and hydroxypropyl cellulose.
  • the cellulose or derivative thereof is methylcellulose or a derivative thereof.
  • the cellulose or derivative thereof is hydroxypropyl methylcellulose (HPMC).
  • HPMC hydroxypropyl methylcellulose
  • the release-retarding ingredient is an acrylic polymer.
  • acrylic polymers include, for example, acrylic acid and methacrylic acid copolymers, methyl methacrylate copolymers, ethoxyethyl methacrylates, cyanoethyl methacrylate, aminoalkyl methacrylate copolymer, poly(acrylic acid), poly(methacrylic acid), methacrylic acid alkylamide copolymer, poly(methyl methacrylate), poly(methacrylic acid anhydride), methyl methacrylate, polymethacrylate, poly(methyl methacrylate) copolymer, polyacrylamide, aminoalkyl methacrylate copolymer, glycidyl methacrylate copolymers, and combinations comprising one or more of the foregoing polymers.
  • the acrylic polymer may comprise fully polymerized copolymers of acrylic and methacrylic acid esters with a low content of quaternary ammonium groups.
  • the release-retarding ingredient is a polyester.
  • polyesters include polyalkylene glycols, poly(glycolide-co-lactide), PEGylated poly(lactic-co-glycolic acid), poly(lactic acid), PEGylated poly(lactic acid), poly(glycolic acid), PEGylated poly(glycolic acid), co-polymers of polylactic and polyglycolic acid, and derivatives thereof.
  • polyesters include, for example, polyanhydrides, poly(ortho ester) PEGylated poly(ortho ester), poly(caprolactone), PEGylated poly(caprolactone), polylysine, PEGylated polylysine, poly(ethylene imine), PEGylated poly(ethylene imine), and derivatives thereof.
  • polyesters include, for example, polycaprolactone, poly(L-lactide-co-L-lysine), poly(serine ester), poly(4-hydroxy-L-proline ester), poly[ ⁇ -(4-aminobutyl)-L-glycolic acid], and derivatives thereof.
  • the release-retarding ingredient is a cross-linked polymer of poly(vinyl-pyrrolidone).
  • the polymer is crosspovidone.
  • the polymer is un-cross-linked poly(vinyl-pyrrolidone).
  • the polymer is povidone.
  • the release-retarding ingredient may be a natural polymer.
  • the natural polymer is a gum, including, for example, xanthan gum, alginic acid, caraya gum, sodium alginate, and/or locust bean gum.
  • the natural polymer may be a protein (e.g. albumin), lipid, nucleic acid, or carbohydrate.
  • inventive nanoparticle compositions may be prepared by any available method.
  • nanoparticle compositions are prepared by chemical means.
  • chemical means often require toxic (typically organic) solvents; in some embodiments, nanoparticle compositions are prepared in accordance with the present invention without utilizing such solvents.
  • nanoparticle compositions are prepared by preparing a premix and subjecting the premix to high shear forces.
  • shear force refers to a force that is parallel to the face of a material, as opposed to a force that is perpendicular to the face of a material.
  • any method known in the art can be used to generate high shear forces.
  • the use of mechanical energy i.e., high shear forces
  • can replace or minimize any requirement to use costly and/or toxic chemical solvents; can increase the speed at which nanoparticles assemble, can increase the yield of nanoparticles generated in a particular mix of components, and/or can greatly reduce the overall cost of preparing nanoparticle compositions.
  • an agent such as a biologically active agent (e.g., botulinum toxin) is incorporated into inventive nanoparticle compositions
  • the use of high shear force can increase the loading capacity of the nanoparticle as compared to traditional methods of forming nanoparticles.
  • loading of agents within or on the surface of nanoparticles typically relies on diffusion of the agent to the interior and/or to the surface of the nanoparticle.
  • the use of high shear force can allow for the manufacture of smaller particles (e.g., on average) and/or a more narrow distribution of particle sizes in a nanoparticle composition.
  • high shear forces are achieved by exposure to high pressure, for example by continuous turbulent flow at high pressure, for example about 15,000 psi. In some embodiments, such high pressure is within the range of about 18,000 to about 26,000 psi; in some embodiments, it is within the range of about 20,000 to 25,000 psi. In some embodiments, high shear forces are characterized by pressures of at least 3,000 psi, 10,000 psi, 15,000 psi, 18,000 psi, 20,000 psi, 22,000 psi, or 24,000 psi.
  • high shear forces are characterized by pressures of 16,000 psi, 17,000 psi, 18,000 psi, 19,000 psi, 20,000 psi, 21,000 psi, 22,000 psi, 23,000 psi, 24,000 psi, or 25,000 psi.
  • cavitation is used to generate high shear forces.
  • high pressure homogenization is used to generate high shear forces.
  • high shear force may be administered by passage through an instrument such as, for example, a Microfluidizer® Processor (Microfluidics Corporation/MFIC Corporation) or other like device.
  • Microfluidizer® Processors provide high pressure and a resultant high shear rate by accelerating the product through microchannels to a high velocity for size reduction to the nanoscale range.
  • the fluid is split in two and is pushed through microchannels with typical dimensions in the order of 75 microns at high velocities (in the range of 50-300 m/s). As the fluid exits the microchannels it forms jets which collide with jets from opposing microchannels.
  • the fluid experiences high shear (up to 10 7 l/s) which is orders of magnitude higher than that of conventional technologies. Jet collisions result in mixing in submicron level. Therefore, high shear and impact are responsible for particle size reduction and mixing of multiphase fluids in the Microfluidizer® technology.
  • a sample is “microfluidized” through exposure to high shear forces for a period of time less than about 10 minutes.
  • the period of time is less than about 9, 8, 7, 6, 5, 4, 3, 2, or 1 minute(s).
  • the period of time is within the range of about 1-2 minutes or less; in some embodiments, the period of time is about 30 seconds.
  • a sample is “microfluidized” through a single exposure to high shear forces; such embodiments are referred to herein as “single pass” microfluidization.
  • the present invention encompasses the recognition that subjecting a premix to high shear forces can generate a nanoparticle composition, and in particular can generate a uniform nanoparticle composition.
  • all of the components present in the final nanoparticle composition are present in the premix and are subjected to high shear force to produce the nanoparticle composition.
  • one or more of the components that are present in the final nanoparticle composition is/are missing from the premix or is/are present in the premix in a smaller amount than in the final nanoparticle composition. That is, in some embodiments of the present invention, one or more materials are added to the nanoparticle composition after the premix is subjected to high shear force.
  • the premix is prepared as a solution prior to application of high shear force.
  • at least one biologically active agent e.g., botulinum toxin
  • the biologically active agent is soluble in at least one of the media (or in a combination of media utilized in the premix). In some embodiments of the invention, such dissolution requires heating; in other embodiments it does not.
  • the premix components may assemble into particles before the application of high shear force. At least some of such particles may be microparticles or even nanoparticles.
  • an inventive nanoparticle composition is prepared from a premix, wherein the premix is selected from the group comprising a suspension or a microemulsion. In some embodiments, however, particle structures do not form in the premix before application of high shear force.
  • the present invention provides methods of using AE nanoparticles and/or nanoparticle compositions by delivering them (optionally in conjunction with a biologically active agent or other substance) to a subject.
  • delivery may be via any route.
  • delivery may be orally, parenterally, intracisternally, intravaginally, subcutaneously, intraperitoneally, intramuscularly, intravenously, transdermally (topically), intradermally, bucally, rectally, and/or opthalmically.
  • the invention provides methods of transdermally delivering a biologically active agent to a subject by administering to the subject one or more AE nanoparticles to the surface of the subject's skin, wherein the biologically active agent is contained within or bound to the surface of the AE nanoparticles.
  • the subject may be a mammal (e.g. human).
  • a composition for transdermal delivery of a biologically active agent may comprise AE nanoparticles containing the agent to be delivered.
  • the biologically active agent may be encapsulated within the AE nanoparticles.
  • the biologically active agent may be bound to the surface of the AE nanoparticles.
  • AE nanoparticles of the present invention can achieve transdermal delivery of a biologically active agent without requiring the use of abrasive or other skin-disrupting agents (whether chemical, mechanical, electrical, magnetic, etc.).
  • a composition for transdermal delivery of a composition comprising AE nanoparticles for transdermal delivery of a biologically active agent may be in the form of a cosmetic formulation including, but not limited to, a skin softener, nutrition lotion type emulsion, cleansing lotion, cleansing cream, skin milk, emollient lotion, massage cream, emollient cream, make-up base, lipstick, facial pack or facial gel, cleaner formulation (e.g. shampoos, rinses, body cleanser, hair-tonics, or soaps), and dermatological composition (e.g. lotions, ointments, gels, creams, patches or sprays).
  • a cosmetic formulation including, but not limited to, a skin softener, nutrition lotion type emulsion, cleansing lotion, cleansing cream, skin milk, emollient lotion, massage cream, emollient cream, make-up base, lipstick, facial pack or facial gel, cleaner formulation (e.g. shampoos, rinses, body cleanser, hair-tonics, or soaps), and
  • a composition for transdermal delivery of a biologically active agent may be in the form of a transdermal patch.
  • adhesive patches are well known in the art (for example, see U.S. Pat. Nos. 296,006 (design); 6,010,715; 5,591,767; 5,008,110; 5,683,712; 5,948,433; and 5,965,154.
  • the transdermal patch may comprise an adhesive layer, which may be applied to a person's skin.
  • the transdermal patch may comprise a depot or reservoir for holding a biologically active agent or composition.
  • the transdermal patch comprises an exterior surface that may prevent leakage of the agent or composition from the depot.
  • the exterior surface of a patch may be non-adhesive.
  • the composition comprising AE nanoparticles for transdermal delivery of a biologically active agent may be incorporated into a patch so that the AE nanoparticles remain stable for extended periods of time.
  • the AE nanoparticles may be incorporated into a polymeric matrix that stabilizes the AE nanoparticles and permits the AE nanoparticles to diffuse from the matrix and from the patch.
  • the AE nanoparticles may be incorporated into the adhesive layer of the patch.
  • the adhesive layer may be heat-activated.
  • temperatures of about 37° C. may cause the adhesive to slowly liquefy so that the AE nanoparticles diffuse through the skin.
  • the adhesive may remain tacky when stored at less than 37° C.
  • the adhesive loses its tackiness as it liquefies at temperatures of about 37° C.
  • the administration of the AE nanoparticles is complete once the patch no longer adheres to the skin.
  • the compositions comprising AE nanoparticles for transdermal delivery of a biologically active agent may be used in an application device that permits application of the composition to a target site on the skin without applying the composition to non-target site areas of the skin.
  • a device may be employed that allows the composition to be applied without first applying the composition to one's fingers, which may lead to undesirable paralysis of the fingers.
  • Suitable devices include spatulas, swabs, syringes without needles, and adhesive patches. Use of spatulas or swabs, or the like may require the device to be inserted into a container containing the composition.
  • Using syringes or adhesive patches may be accomplished by filling the syringe or patch with the composition.
  • the composition may be topically spread by the spatulas or swabs, or may be expelled from the syringes onto the person's skin.
  • the biologically active agent may be one or more botulinum toxin peptides or protein complexes.
  • the botulinum toxin may be one or more of botulinum toxin serotypes A, B, C 1 , C 2 , D, E, F, or G.
  • the botulinum toxin may be an isolated and/or purified botulinum toxin.
  • the botulinum toxin may be a partially-isolated and/or partially-purified botulinum toxin.
  • the botulinum toxin may be a native botulinum complex.
  • the botulinum toxin may be associated with non-toxin proteins.
  • the botulinum toxin may be a recombinantly-made botulinum toxin.
  • the botulinum toxin within a composition for transdermal delivery may be present in an amount so that between about 10 ⁇ 3 U/kg and 10 U/kg pass through a patient's skin. In some embodiments, the botulinum toxin may be present in an amount so that between about 10 ⁇ 2 U/kg and about 1 U/kg pass through the patient's skin. In some embodiments, the botulinum toxin may be present in an amount so that between about 10 ⁇ 1 U/kg and about 1 U/kg pass through the patient's skin. In some embodiments, the botulinum toxin may be present in an amount so that between about 0.1 U and about 5 U pass through the patient's skin. As used herein, “Units” (“U”) are biologically equivalent or bioactively equivalent to Units defined by commercial manufacturers of botulinum toxin.
  • dosages of botulinum toxin can range from as low as about 1 U to as high as about 20,000 U.
  • the particular dosages may vary depending on the condition being treated and therapeutic regime being utilized. For example, treatment of subdermal, hyperactive muscles may require high transdermal dosages (for example, 200 U to 20,000 U) of botulinum toxin. In comparison, treatment of neurogenic inflammation or hyperactive sweat glands may require relatively small transdermal dosages (for example, about 1 U to about 1,000 U) of botulinum toxin.
  • the composition may comprise an amount of botulinum toxin sufficient to achieve a therapeutic effect lasting between 1 month and 5 years.
  • the composition comprising botulinum toxin may be formulated to avoid potential complications including, but not limited to, systemic toxicity or botulism poisoning.
  • the present invention provides methods of treating facial wrinkles.
  • nanoparticle compositions comprising AE nanoparticles for the transdermal delivery of a biologically active agent may be used to treat facial wrinkles.
  • nanoparticle compositions comprising AE nanoparticles for the transdermal delivery of botulinum toxin may be used to treat facial wrinkles.
  • facial wrinkles may include glabellar wrinkles, facial lines (e.g. hyperkinetic facial lines), forehead frown lines, midfacial wrinkles, mouth wrinkles, neck lines and banding (e.g. platysma bands), and chin creases.
  • the present invention provides methods of treating neuromuscular disorders and conditions in a subject.
  • nanoparticle compositions comprising AE nanoparticles for the transdermal delivery of a biologically active agent may be used to treat neuromuscular disorders and conditions involving muscular spasm and/or contracture.
  • nanoparticle compositions comprising AE nanoparticles for the transdermal delivery of botulinum toxin may be used to treat neuromuscular disorders and conditions.
  • neuromuscular disorders and conditions involving muscular spasm and/or contracture include, but are not limited to, various forms of palsy, facial contracture, dystonia, hemifacial spasm, tremor, spasticity (e.g.
  • the present invention does not provide methods of treating neuromuscular disorders and conditions involving muscular spasm and/or contracture in a subject.
  • the present invention provides methods of treating hyperhidrosis (i.e., a medical condition in which a person sweats excessively and unpredictably) in a subject.
  • hyperhidrosis i.e., a medical condition in which a person sweats excessively and unpredictably
  • nanoparticle compositions comprising AE nanoparticles for the transdermal delivery of a biologically active agent may be used to treat hyperhidrosis.
  • nanoparticle compositions comprising AE nanoparticles for the transdermal delivery of botulinum toxin may be used to treat hyperhidrosis.
  • the present invention does not provide methods of treating hyperhidrosis in a subject.
  • the present invention provides methods of treating headache in a subject.
  • nanoparticle compositions comprising AE nanoparticles for the transdermal delivery of a biologically active agent may be used to treat headache.
  • nanoparticle compositions comprising AE nanoparticles for the transdermal delivery of botulinum toxin may be used to treat headache.
  • the present invention does not provide methods of treating headache in a subject.
  • the present invention provides methods of treating prostate hyperplasia in a subject.
  • nanoparticle compositions comprising AE nanoparticles for the transdermal delivery of a biologically active agent may be used to treat prostate hyperplasia.
  • nanoparticle compositions comprising AE nanoparticles for the transdermal delivery of botulinum toxin may be used to treat prostate hyperplasia.
  • the present invention does not provide methods of treating prostate hyperplasia in a subject.
  • the present invention provides a method of imaging a disorder (e.g. cancer) in a subject by labeling one or more AE nanoparticles with a reporter group and with a targeting agent that binds to a target associated with the disorder; administering the labeled particles to the subject under conditions and in an amount sufficient to bind to the target; and imaging the reporter group, thereby imaging the disorder.
  • a disorder e.g. cancer
  • nanoparticle compositions may comprise AE nanoparticles which contain drugs, including but not limited to, antibiotics, anti-viral agents, anesthetics, anticoagulants, anti-cancer agents, inhibitors of enzymes, steroidal agents, anti-inflammatory agents, anti-neoplastic agents, antigens, vaccines, antibodies, decongestants, antihypertensives, sedatives, birth control agents, progestational agents, anti-cholinergics, analgesics, anti-depressants, anti-psychotics, ⁇ -adrenergic blocking agents, diuretics, cardiovascular active agents, vasoactive agents, hormones (e.g. insulin, estradiol), and non-steroidal anti-inflammatory agents.
  • drugs including but not limited to, antibiotics, anti-viral agents, anesthetics, anticoagulants, anti-cancer agents, inhibitors of enzymes, steroidal agents, anti-inflammatory agents, anti-neoplastic agents, antigens, vaccines, antibodies, decongestant
  • the present invention provides AE nanoparticles.
  • the present invention provides for pharmaceutical compositions comprising AE nanoparticles, as described herein.
  • the present invention provides pharmaceutical compositions comprising AE nanoparticles containing a therapeutically effective amount of a biologically active agent.
  • Such pharmaceutical compositions may optionally comprise one or more additional therapeutically-active substances.
  • the compositions are administered to humans.
  • compositions suitable for administration to humans are principally directed to pharmaceutical compositions which are suitable for ethical administration to humans, it will be understood by the skilled artisan that such compositions are generally suitable for administration to animals of all sorts. Modification of pharmaceutical compositions suitable for administration to humans in order to render the compositions suitable for administration to various animals is well understood, and the ordinarily skilled veterinary pharmacologist can design and/or perform such modification with merely ordinary, if any, experimentation.
  • Subjects to which administration of the pharmaceutical compositions of the invention is contemplated include, but are not limited to, humans and/or other primates; mammals, including commercially relevant mammals such as cattle, pigs, horses, sheep, cats, and/or dogs; and/or birds, including commercially relevant birds such as chickens, ducks, geese, and/or turkeys.
  • compositions described herein may be prepared by any method known or hereafter developed in the art of pharmacology.
  • preparatory methods include the step of bringing the active ingredient into association with a carrier and/or one or more other accessory ingredients, and then, if necessary and/or desirable, shaping and/or packaging the product into a desired single- or multi-dose unit.
  • a pharmaceutical composition of the invention may be prepared, packaged, and/or sold in bulk, as a single unit dose, and/or as a plurality of single unit doses.
  • a “unit dose” is discrete amount of the pharmaceutical composition comprising a predetermined amount of the active ingredient.
  • the amount of the active ingredient is generally equal to the dosage of the active ingredient which would be administered to a subject and/or a convenient fraction of such a dosage such as, for example, one-half or one-third of such a dosage.
  • compositions of the invention will vary, depending upon the identity, size, and/or condition of the subject treated and further depending upon the route by which the composition is to be administered.
  • the composition may comprise between 0.1% and 100% (w/w) active ingredient.
  • a pharmaceutically acceptable derivative includes, but is not limited to, pharmaceutically acceptable salts, esters, salts of such esters, or any other adduct or derivative which upon administration to a patient in need is capable of providing, directly or indirectly, a compound as otherwise described herein, or a metabolite or residue thereof, e.g., a prodrug.
  • salts refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio.
  • Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge, et al. describe pharmaceutically acceptable salts in detail (1977 , J. Pharm. Sci., 66:1; incorporated herein by reference). Salts can be prepared in situ during the final isolation and purification of the compounds of the invention, or separately by reacting the free base functionality with a suitable organic or inorganic acid.
  • Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid or by using other methods used in the art such as ion exchange.
  • inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid
  • organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid or by using other methods used in the art such as ion exchange.
  • salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hernisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate,
  • alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like.
  • Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, loweralkyl sulfonate, and aryl sulfonate.
  • ester refers to esters which hydrolyze in vivo and include those that break down readily in the human body to leave the parent compound or a salt thereof.
  • Suitable ester groups include, for example, those derived from pharmaceutically acceptable aliphatic carboxylic acids, particularly alkanoic, alkenoic, cycloalkanoic and alkanedioic acids, in which each alkyl or alkenyl moiety advantageously has not more than 6 carbon atoms.
  • esters include formates, acetates, propionates, butyrates, acrylates and ethylsuccinates.
  • the esters are cleaved by enzymes such as esterases.
  • prodrugs refers to those prodrugs of the compounds of the present invention which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals with undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the invention.
  • prodrug refers to compounds that are rapidly transformed in vivo to yield the parent compound of the above formula, for example by hydrolysis in blood. A thorough discussion is provided in T. Higuchi and V. Stella, Pro - drugs as Novel Delivery Systems , Vol. 14 of the A.C.S. Symposium Series and in E. B. Roche, ed., Bioreversible Carriers in Drug Design , American Pharmaceutical Association and Pergamon Press, 1987 (both of which are incorporated herein by reference).
  • the pharmaceutical formulations of the present invention may additionally comprise a pharmaceutically acceptable excipient, which, as used herein, includes any and all solvents, dispersion media, diluents, or other liquid vehicles, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired.
  • a pharmaceutically acceptable excipient includes any and all solvents, dispersion media, diluents, or other liquid vehicles, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired.
  • Remington's The Science and Practice of Pharmacy, 21 st Edition, A. R. Gennaro, discloses various carriers used in formulating pharmaceutical compositions and known techniques for the preparation thereof.
  • any conventional carrier medium is incompatible with a substance or its derivatives, such as by producing any undesirable biological effect or otherwise interacting in a deleterious manner with any other component(s) of the pharmaceutical composition, its use is contemplated to be within the scope of this invention.
  • the pharmaceutically acceptable excipient is at least 95%, 96%, 97%, 98%, 99%, or 100% pure. In some embodiments, the excipient is approved for use in humans and for veterinary use. In some embodiments, the excipient is approved by United States Food and Drug Administration. In some embodiments, the excipient is pharmaceutical grade. In some embodiments, the excipient meets the standards of the United States Pharmacopoeia (USP), the European Pharmacopoeia (EP), the British Pharmacopoeia, and/or the International Pharmacopoeia.
  • USP United States Pharmacopoeia
  • EP European Pharmacopoeia
  • British Pharmacopoeia the British Pharmacopoeia
  • International Pharmacopoeia International Pharmacopoeia
  • compositions used in the manufacture of pharmaceutical compositions include, but are not limited to, inert diluents, dispersing and/or granulating agents, surface active agents and/or emulsifiers, disintegrating agents, binding agents, preservatives, buffering agents, lubricating agents, and/or oils. Such excipients may optionally be included in the inventive formulations. Excipients such as cocoa butter and suppository waxes, coloring agents, coating agents, sweetening, flavoring, and perfuming agents can also be present in the composition, according to the judgment of the formulator.
  • Exemplary diluents include, but are not limited to, calcium carbonate, sodium carbonate, calcium phosphate, dicalcium phosphate, calcium sulfate, calcium hydrogen phosphate, sodium phosphate lactose, sucrose, cellulose, microcrystalline cellulose, kaolin, mannitol, sorbitol, inositol, sodium chloride, dry starch, cornstarch, powdered sugar, etc., and combinations thereof.
  • Exemplary granulating and/or dispersing agents include, but are not limited to, potato starch, corn starch, tapioca starch, sodium starch glycolate, clays, alginic acid, guar gum, citrus pulp, agar, bentonite, cellulose and wood products, natural sponge, cation-exchange resins, calcium carbonate, silicates, sodium carbonate, cross-linked poly(vinyl-pyrrolidone) (crospovidone), sodium carboxymethyl starch (sodium starch glycolate), carboxymethyl cellulose, cross-linked sodium carboxymethyl cellulose (croscarmellose), methylcellulose, pregelatinized starch (starch 1500), microcrystalline starch, water insoluble starch, calcium carboxymethyl cellulose, magnesium aluminum silicate (Veegum), sodium lauryl sulfate, quaternary ammonium compounds, etc., and combinations thereof.
  • Exemplary surface active agents and/or emulsifiers include, but are not limited to, natural emulsifiers (e.g. acacia, agar, alginic acid, sodium alginate, tragacanth, chondrux, cholesterol, xanthan, pectin, gelatin, egg yolk, casein, wool fat, cholesterol, wax, and lecithin), colloidal clays (e.g. bentonite [aluminum silicate] and Veegum [magnesium aluminum silicate]), long chain amino acid derivatives, high molecular weight alcohols (e.g.
  • natural emulsifiers e.g. acacia, agar, alginic acid, sodium alginate, tragacanth, chondrux, cholesterol, xanthan, pectin, gelatin, egg yolk, casein, wool fat, cholesterol, wax, and lecithin
  • colloidal clays e.g. bentonite [aluminum silicate]
  • stearyl alcohol cetyl alcohol, oleyl alcohol, triacetin monostearate, ethylene glycol distearate, glyceryl monostearate, and propylene glycol monostearate, polyvinyl alcohol), carbomers (e.g. carboxy polymethylene, polyacrylic acid, acrylic acid polymer, and carboxyvinyl polymer), carrageenan, cellulosic derivatives (e.g. carboxymethylcellulose sodium, powdered cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose), sorbitan fatty acid esters (e.g.
  • Cremophor polyoxyethylene ethers, (e.g. polyoxyethylene lauryl ether [Brij 30]), poly(vinyl-pyrrolidone), diethylene glycol monolaurate, triethanolamine oleate, sodium oleate, potassium oleate, ethyl oleate, oleic acid, ethyl laurate, sodium lauryl sulfate, Pluronic F 68, Poloxamer 188, cetrimonium bromide, cetylpyridinium chloride, benzalkonium chloride, docusate sodium, etc. and/or combinations thereof.
  • polyoxyethylene ethers e.g. polyoxyethylene lauryl ether [Brij 30]
  • poly(vinyl-pyrrolidone) diethylene glycol monolaurate
  • triethanolamine oleate sodium oleate
  • potassium oleate ethyl oleate
  • oleic acid ethyl laurate
  • Exemplary binding agents include, but are not limited to, starch (e.g. cornstarch and starch paste); gelatin; sugars (e.g. sucrose, glucose, dextrose, dextrin, molasses, lactose, lactitol, mannitol,); natural and synthetic gums (e.g.
  • acacia sodium alginate, extract of Irish moss, panwar gum, ghatti gum, mucilage of isapol husks, carboxymethylcellulose, methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, microcrystalline cellulose, cellulose acetate, poly(vinyl-pyrrolidone), magnesium aluminum silicate (Veegum), and larch arabogalactan); alginates; polyethylene oxide; polyethylene glycol; inorganic calcium salts; silicic acid; polymethacrylates; waxes; water; alcohol; etc.; and combinations thereof.
  • Exemplary preservatives may include antioxidants, chelating agents, antimicrobial preservatives, antifungal preservatives, alcohol preservatives, acidic preservatives, and other preservatives.
  • Exemplary antioxidants include, but are not limited to, alpha tocopherol, ascorbic acid, acorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, monothioglycerol, potassium metabisulfite, propionic acid, propyl gallate, sodium ascorbate, sodium bisulfite, sodium metabisulfite, and sodium sulfite.
  • Exemplary chelating agents include ethylenediaminetetraacetic acid (EDTA), citric acid monohydrate, disodium edetate, dipotassium edetate, edetic acid, fumaric acid, malic acid, phosphoric acid, sodium edetate, tartaric acid, and trisodium edetate.
  • EDTA ethylenediaminetetraacetic acid
  • citric acid monohydrate disodium edetate
  • dipotassium edetate dipotassium edetate
  • edetic acid fumaric acid, malic acid
  • phosphoric acid sodium edetate
  • tartaric acid tartaric acid
  • trisodium edetate trisodium edetate.
  • antimicrobial preservatives include, but are not limited to, benzalkonium chloride, benzethonium chloride, benzyl alcohol, bronopol, cetrimide, cetylpyridinium chloride, chlorhexidine, chlorobutanol, chlorocresol, chloroxylenol, cresol, ethyl alcohol, glycerin, hexetidine, imidurea, phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric nitrate, propylene glycol, and thimerosal.
  • Exemplary antifungal preservatives include, but are not limited to, butyl paraben, methyl paraben, ethyl paraben, propyl paraben, benzoic acid, hydroxybenzoic acid, potassium benzoate, potassium sorbate, sodium benzoate, sodium propionate, and sorbic acid.
  • Exemplary alcohol preservatives include, but are not limited to, ethanol, polyethylene glycol, phenol, phenolic compounds, bisphenol, chlorobutanol, hydroxybenzoate, and phenylethyl alcohol.
  • Exemplary acidic preservatives include, but are not limited to, vitamin A, vitamin C, vitamin E, beta-carotene, citric acid, acetic acid, dehydroacetic acid, ascorbic acid, sorbic acid, and phytic acid.
  • preservatives include, but are not limited to, tocopherol, tocopherol acetate, deteroxime mesylate, cetrimide, butylated hydroxyanisol (BHA), butylated hydroxytoluened (BHT), ethylenediamine, sodium lauryl sulfate (SLS), sodium lauryl ether sulfate (SLES), sodium bisulfite, sodium metabisulfite, potassium sulfite, potassium metabisulfite, Glydant Plus, Phenonip, methylparaben, Germall 115, Germaben II, Neolone, Kathon, and Euxyl.
  • the preservative is an anti-oxidant.
  • the preservative is a chelating agent.
  • Exemplary buffering agents include, but are not limited to, citrate buffer solutions, acetate buffer solutions, phosphate buffer solutions, ammonium chloride, calcium carbonate, calcium chloride, calcium citrate, calcium glubionate, calcium gluceptate, calcium gluconate, D-gluconic acid, calcium glycerophosphate, calcium lactate, propanoic acid, calcium levulinate, pentanoic acid, dibasic calcium phosphate, phosphoric acid, tribasic calcium phosphate, calcium hydroxide phosphate, potassium acetate, potassium chloride, potassium gluconate, potassium mixtures, dibasic potassium phosphate, monobasic potassium phosphate, potassium phosphate mixtures, sodium acetate, sodium bicarbonate, sodium chloride, sodium citrate, sodium lactate, dibasic sodium phosphate, monobasic sodium phosphate, sodium phosphate mixtures, tromethamine, magnesium hydroxide, aluminum hydroxide, alginic acid, pyrogen-free water, isotonic
  • Exemplary lubricating agents include, but are not limited to, magnesium stearate, calcium stearate, stearic acid, silica, talc, malt, glyceryl behanate, hydrogenated vegetable oils, polyethylene glycol, sodium benzoate, sodium acetate, sodium chloride, leucine, magnesium lauryl sulfate, sodium lauryl sulfate, etc., and combinations thereof.
  • oils include, but are not limited to, almond, apricot kernel, avocado, babassu, bergamot, black current seed, borage, cade, chamomile, canola, caraway, carnauba, castor, cinnamon, cocoa butter, coconut, cod liver, coffee, corn, cotton seed, emu, eucalyptus, evening primrose, fish, flaxseed, geraniol, gourd, grape seed, hazel nut, hyssop, isopropyl myristate, jojoba, kukui nut, lavandin, lavender, lemon, litsea cubeba, macadamia nut, mallow, mango seed, meadowfoam seed, mink, nutmeg, olive, orange, orange roughy, palm, palm kernel, peach kernel, peanut, poppy seed, pumpkin seed, rapeseed, rice bran, rosemary, safflower, sandalwood, sasquana, s
  • the pharmaceutical compositions may be administered to animals, preferably mammals (e.g., domesticated animals, cats, dogs, mice, rats), and more preferably humans. Any method of administration may be used to deliver the pharmaceutical compositions to the animal. In certain embodiments, the pharmaceutical composition is administered orally. In other embodiments, the pharmaceutical composition is administered parenterally.
  • a method for the treatment of facial wrinkles comprising administering a therapeutically effective amount of AE nanoparticles comprising botulinum toxin to a subject in need thereof, in such amounts and for such time as is necessary to achieve the desired result.
  • a “therapeutically effective amount” of the AE nanoparticles comprising botulinum toxin is that amount effective for treating facial wrinkles including, but not limited to, glabellar wrinkles, facial lines (e.g. hyperkinetic facial lines), forehead frown lines, midfacial wrinkles, mouth wrinkles, neck lines and banding (e.g. platysma bands), and chin creases.
  • a method for the treatment of hyperhidrosis comprising administering a therapeutically effective amount of AE nanoparticles comprising botulinum toxin to the hands, feet, and/or underarms of a subject in need thereof, in such amounts and for such time as is necessary to achieve the desired result.
  • compositions may be administered using any amount and any route of administration effective for treating facial wrinkles.
  • the exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the infection, the particular composition, its mode of administration, its mode of activity, and the like.
  • the compositions of the invention are preferably formulated in dosage unit form for ease of administration and uniformity of dosage. It will be understood, however, that the total daily usage of the compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment.
  • the specific therapeutically effective dose level for any particular patient or organism will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed; and like factors well known in the medical arts.
  • compositions of the present invention may be administered by any route.
  • the pharmaceutical compositions of the present invention are administered variety of routes, including oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, subcutaneous, intraventricular, transdermal, interdermal, rectal, intravaginal, intraperitoneal, topical (as by powders, ointments, creams, and/or drops), mucosal, bucal, enteral, sublingual, and/or as an oral spray, nasal spray, and/or aerosol.
  • the most appropriate route of administration will depend upon a variety of factors including the nature of the agent (e.g., its stability in the environment of the gastrointestinal tract), the condition of the patient (e.g., whether the patient is able to tolerate oral administration), etc.
  • the oral and/or nasal spray and/or aerosol route is most commonly used to deliver therapeutic agents directly to the lungs and/or respiratory system.
  • the invention encompasses the delivery of the inventive pharmaceutical composition by any appropriate route taking into consideration likely advances in the sciences of drug delivery.
  • the compounds of the invention may be administered orally or parenterally at dosage levels sufficient to deliver from about 0.001 mg/kg to about 100 mg/kg, from about 0.01 mg/kg to about 50 mg/kg, preferably from about 0.1 mg/kg to about 40 mg/kg, preferably from about 0.5 mg/kg to about 30 mg/kg, from about 0.01 mg/kg to about 10 mg/kg, from about 0.1 mg/kg to about 10 mg/kg, and more preferably from about 1 mg/kg to about 25 mg/kg, of subject body weight per day, one or more times a day, to obtain the desired therapeutic effect.
  • the desired dosage may be delivered three times a day, two times a day, once a day, every other day, every third day, every week, every two weeks, every three weeks, or every four weeks.
  • the desired dosage may be delivered using multiple administrations (e.g., two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, or more administrations).
  • Liquid dosage forms for oral and parenteral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
  • the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
  • inert diluents commonly used in the art such as, for example, water or
  • the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
  • adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
  • solubilizing agents such an Cremophor, alcohols, oils, modified oils, glycols, polysorbates, cyclodextrins, polymers, and combinations thereof.
  • sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.
  • acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil can be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid are used in the preparation of injectables.
  • the injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
  • the rate of drug release can be controlled.
  • biodegradable polymers include poly(orthoesters) and poly(anhydrides).
  • Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissues.
  • compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
  • suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
  • the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and gly
  • Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
  • the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
  • the active compounds can also be in micro-encapsulated form with one or more excipients as noted above.
  • the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art.
  • the active compound may be admixed with at least one inert diluent such as sucrose, lactose or starch.
  • Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose.
  • the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner.
  • buffering agents include polymeric substances and waxes.
  • Dosage forms for topical and/or transdermal administration of a compound of this invention may include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants and/or patches.
  • the active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and/or any needed preservatives and/or buffers as may be required.
  • the present invention contemplates the use of transdermal patches, which often have the added advantage of providing controlled delivery of a compound to the body.
  • Such dosage forms may be prepared, for example, by dissolving and/or dispensing the compound in the proper medium.
  • the rate may be controlled by either providing a rate controlling membrane and/or by dispersing the compound in a polymer matrix and/or gel.
  • Suitable devices for use in delivering intradermal pharmaceutical compositions described herein include short needle devices such as those described in U.S. Pat. Nos. 4,886,499; 5,190,521; 5,328,483; 5,527,288; 4,270,537; 5,015,235; 5,141,496; and 5,417,662 (all of which are incorporated herein by reference).
  • Intradermal compositions may be administered by devices which limit the effective penetration length of a needle into the skin, such as those described in PCT publication WO 99/34850 (incorporated herein by reference) and functional equivalents thereof.
  • Jet injection devices which deliver liquid vaccines to the dermis via a liquid jet injector and/or via a needle which pierces the stratum corneum and produces a jet which reaches the dermis are suitable. Jet injection devices are described, for example, in U.S. Pat. Nos.
  • Ballistic powder/particle delivery devices which use compressed gas to accelerate vaccine in powder form through the outer layers of the skin to the dermis are suitable.
  • conventional syringes may be used in the classical mantoux method of intradermal administration.
  • Formulations suitable for topical administration include, but are not limited to, liquid and/or semi liquid preparations such as liniments, lotions, oil in water and/or water in oil emulsions such as creams, ointments and/or pastes, and/or solutions and/or suspensions.
  • Topically-administrable formulations may, for example, comprise from about 1% to about 10% (w/w) active ingredient, although the concentration of the active ingredient may be as high as the solubility limit of the active ingredient in the solvent.
  • Formulations for topical administration may further comprise one or more of the additional ingredients described herein.
  • a pharmaceutical composition of the invention may be prepared, packaged, and/or sold in a formulation suitable for pulmonary administration via the buccal cavity.
  • a formulation may comprise dry particles which comprise the active ingredient and which have a diameter in the range from about 0.5 to about 7 nanometers or from about 1 to about 6 nanometers.
  • Such compositions are conveniently in the form of dry powders for administration using a device comprising a dry powder reservoir to which a stream of propellant may be directed to disperse the powder and/or using a self propelling solvent/powder dispensing container such as a device comprising the active ingredient dissolved and/or suspended in a low-boiling propellant in a sealed container.
  • Such powders comprise particles wherein at least 98% of the particles by weight have a diameter greater than 0.5 nanometers and at least 95% of the particles by number have a diameter less than 7 nanometers. Alternatively, at least 95% of the particles by weight have a diameter greater than 1 nanometer and at least 90% of the particles by number have a diameter less than 6 nanometers.
  • Dry powder compositions may include a solid fine powder diluent such as sugar and are conveniently provided in a unit dose form.
  • Low boiling propellants generally include liquid propellants having a boiling point of below 65.degree. F. at atmospheric pressure. Generally the propellant may constitute 50 to 99.9% (w/w) of the composition, and the active ingredient may constitute 0.1 to 20% (w/w) of the composition.
  • the propellant may further comprise additional ingredients such as a liquid non-ionic and/or solid anionic surfactant and/or a solid diluent (which may have a particle size of the same order as particles comprising the active ingredient).
  • compositions of the invention formulated for pulmonary delivery may provide the active ingredient in the form of droplets of a solution and/or suspension.
  • Such formulations may be prepared, packaged, and/or sold as aqueous and/or dilute alcoholic solutions and/or suspensions, optionally sterile, comprising the active ingredient, and may conveniently be administered using any nebulization and/or atomization device.
  • Such formulations may further comprise one or more additional ingredients including, but not limited to, a flavoring agent such as saccharin sodium, a volatile oil, a buffering agent, a surface active agent, and/or a preservative such as methylhydroxybenzoate.
  • the droplets provided by this route of administration may have an average diameter in the range from about 0.1 nm to about 200 nm.
  • formulations described herein as being useful for pulmonary delivery are useful for intranasal delivery of a pharmaceutical composition of the invention.
  • Another formulation suitable for intranasal administration is a coarse powder comprising the active ingredient and having an average particle from about 0.2 ⁇ m to 500 ⁇ m.
  • Such a formulation is administered in the manner in which snuff is taken, i.e. by rapid inhalation through the nasal passage from a container of the powder held close to the nares.
  • Formulations suitable for nasal administration may, for example, comprise from about as little as 0.1% (w/w) and as much as 100% (w/w) of the active ingredient, and may comprise one or more of the additional ingredients described herein.
  • a pharmaceutical composition of the invention may be prepared, packaged, and/or sold in a formulation suitable for buccal administration.
  • Such formulations may, for example, be in the form of tablets and/or lozenges made using conventional methods, and may, for example, 0.1% to 20% (w/w) active ingredient, the balance comprising an orally dissolvable and/or degradable composition and, optionally, one or more of the additional ingredients described herein.
  • formulations suitable for buccal administration may comprise a powder and/or an aerosolized and/or atomized solution and/or suspension comprising the active ingredient.
  • Such powdered, aerosolized, and/or aerosolized formulations when dispersed, may have an average particle and/or droplet size in the range from about 0.1 nm to about 200 nm, and may further comprise one or more of the additional ingredients described herein.
  • a pharmaceutical composition of the invention may be prepared, packaged, and/or sold in a formulation suitable for ophthalmic administration.
  • Such formulations may, for example, be in the form of eye drops including, for example, a 0.1%/1.0% (w/w) solution and/or suspension of the active ingredient in an aqueous or oily liquid carrier.
  • Such drops may further comprise buffering agents, salts, and/or one or more other of the additional ingredients described herein.
  • Other opthalmically-administrable formulations which are useful include those which comprise the active ingredient in microcrystalline form and/or in a liposomal preparation. Ear drops and/or eye drops are contemplated as being within the scope of this invention.
  • the compounds and pharmaceutical compositions of the present invention can be employed in combination therapies.
  • the particular combination of therapies (therapeutics or procedures) to employ in a combination regimen will take into account compatibility of the desired therapeutics and/or procedures and the desired therapeutic effect to be achieved.
  • the therapies employed may achieve a desired effect for the same disorder (for example, an inventive compound may be administered concurrently with another anticancer agent), or they may achieve different effects (e.g., control of any adverse effects).
  • compositions of the present invention may be administered either alone or in combination with one or more other therapeutic agents.
  • the compositions can be administered concurrently with, prior to, or subsequent to, one or more other desired therapeutics or medical procedures. In general, each agent will be administered at a dose and/or on a time schedule determined for that agent.
  • the invention encompasses the delivery of the inventive pharmaceutical compositions in combination with agents that may improve their bioavailability, reduce and/or modify their metabolism, inhibit their excretion, and/or modify their distribution within the body.
  • the particular combination of therapies (therapeutics and/or procedures) to employ in a combination regimen will take into account compatibility of the desired therapeutics and/or procedures and/or the desired therapeutic effect to be achieved. It will be appreciated that the therapies employed may achieve a desired effect for the same disorder (for example, an inventive compound may be administered concurrently with another agent used to treat the same disorder), and/or they may achieve different effects (e.g., control of any adverse effects).
  • compositions of the present invention may be administered alone and/or in combination with other agents that are used to treat the symptoms of facial wrinkles.
  • the pharmaceutical compositions of the present invention could be administered in combination with agents such as retinoic acid, vitamin C and/or E, and/or hyaluronic acid, pentapeptides (e.g., lys-thr-thr-lys-ser), and/or hexapeptides (e.g. acetyl hexapeptide-3, also known as Argireline), depending on the route of administration.
  • Novel compositions comprising pentapeptides and hexapeptides are further described in PCT application serial number PCT/US07/_______ entitled “Peptide Nanoparticles and Uses Thereof,” filed on Nov. 30, 2007.
  • therapeutically active agents utilized in combination may be administered together in a single composition or administered separately in different compositions.
  • agents utilized in combination with be utilized at levels that do not exceed the levels at which they are utilized individually. In some embodiments, the levels utilized in combination will be lower than those utilized individually.
  • kits for conveniently and/or effectively carrying out the methods in accordance with the present invention.
  • an inventive pharmaceutical pack and/or kit comprises one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention.
  • kits are especially suited for the delivery of solid oral forms such as tablets and/or capsules.
  • a kit includes a number of unit dosages, and may include a card having the dosages oriented in the order of their intended use.
  • a memory aid may be provided, for example in the form of numbers, letters, and/or other markings and/or with a calendar insert, designating the days in the treatment schedule in which the dosages can be administered.
  • placebo dosages, and/or calcium dietary supplements may be included to provide a kit in which a dosage is taken every day.
  • Optionally associated with such container(s) may be a notice in the form prescribed by a governmental agency regulating the manufacture, use and/or sale of pharmaceutical products, which notice reflects approval by the agency of manufacture, use and/or sale for human administration.
  • kits comprising AE nanoparticles of the invention and/or instructional materials which describe administering the inventive AE nanoparticles to a cell and/or a tissue of a subject.
  • a kit may comprise a dispersion medium suitable for dissolving and/or suspending the inventive AE nanoparticles prior to administering the compound to the subject.
  • a mixture of 2.5 g of soybean oil and 2.5 g polysorbate 80 (Tween-80) was prepared. The mixture was stirred and heated at 40° C. for 5 minutes. 50 ml deionized water was added, and the resulting mixture was stirred and heated at 40° C. for 10 minutes. 5 ml DMSO containing 0.905 g pullulan and polycaprolactone was added, and the resulting mixture was stirred and heated at 45° C. for 10 minutes. 5 ml was taken for a pre-process sample. The remaining mixture was microfluidized in a single pass at 24,000 psi. The particle size of the pre-process sample was >4000 nm. The particle size after microfluidization was 155 nm.
  • a mixture of 100 ⁇ l of microfluidized sample and 900 ⁇ l of reagent (0.1 M sodium phosphate buffer, 1 mM EDTA, 0.25% Triton X-100, 160 IU/mL of triglyceride hydrolase, and 1 IU/ml of cholesterol esterase) was prepared in a 8 ml glass vial.
  • the resulting mixture was incubated at ambient temperature in the dark for 1 hour. 100 ⁇ l of 5% sodium dodecyl sulfate was added, and the resulting mixture was vortexed for 30 seconds. 1 ml of ethanol was added, and the resulting mixture was vortexed for 30 seconds. 100 ⁇ l of an internal standard was added, and the resulting mixture was vortexed for 30 seconds. 4 ml of a 1:1 mixture of hexane:ether with 1% ethanol and 0.1% BHT was added. Ethanol and BHT stabilize the ether to prevent peroxide formation. The resulting mixture was vortexed for 60 seconds then centrifuged for 2 minutes on medium speed.
  • the supernatant was extracted with a glass pipette and was stored at ⁇ 80° C. for up to 30 days.
  • the supernatant was evaporated and redissolved in 40 ⁇ l of methanol. 30 ⁇ l was injected into an high-pressure liquid chromatography (HPLC) apparatus.
  • HPLC high-pressure liquid chromatography
  • Botulinum Toxin A Formulation with Pullulan and Polycaprolactone
  • a mixture of 1.6 g of soybean oil and 1.6 g of polysorbate 80 (Tween-80) is prepared and stirred for five minutes.
  • a mixture of 100 ng of botulinum toxin A and 20 ml 0.9% saline is prepared and stirred for five minutes.
  • the mixture of saline and botulinum toxin A is added to the mixture of oil and Tween-80 and stirred for 10 minutes.
  • 5 ml of DMSO containing 0.905 grams pullulan and polycaprolactone are added, and the resulting mixture is stirred for 10 minutes.
  • a 5 ml pre-process sample is taken. The remaining mixture is microfluidized in a single pass at 24,000 psi. The particle size before and after microfluidization is measured.
  • Vitamin E Formulation with Pullulan and Polycaprolactone
  • a mixture of 2.5 g soybean oil and 1 g vitamin E is prepared.
  • 2.5 g polysorbate 80 (Tween-80) is added.
  • the resulting mixture is stirred and heated at 40° C. for 5 minutes.
  • 50 ml water is added to the mixture, and the resulting mixture is stirred and heated at 40° C. for 10 minutes.
  • 5 ml DMSO containing 0.905 g pullulan and polycaprolactone is added.
  • the resulting mixture is stirred and heated at 45° C. for 10 minutes.
  • a 5 ml pre-process sample is taken.
  • the remaining mixture is microfluidized in a single pass at 24,000 psi. The particle size before and after microfluidization is measured.
  • Delta tocopherol concentrations can be measured for a patient blood plasma or for nanoparticle compositions. Delta tocopherol concentrations are determined by adding 200 ⁇ L of plasma or nanoparticle composition with 10 ⁇ L of retinyl acetate (internal standard; 10 ⁇ g/mL) and 200 ⁇ L of ethanol containing butylated hydroxytoluene (BHT) (10 mg/L) and 1.0 mL hexane followed by vortex mixing. The samples are centrifuged at 500 ⁇ g for 5 minutes and the organic layer transferred to fresh tube. The sample residues are re-extracted with 1.0 mL of hexane and the organic layers are combined.
  • retinyl acetate internal standard
  • BHT butylated hydroxytoluene
  • the organic layers are evaporated under N 2 and reconstituted with 200 ⁇ L of ethanol containing BHT (10 mg/dL) and injected into an HPLC.
  • the HPLC system is a Model 5600 CoulArray 8-channel system with two Model 580 pumps, a high-pressure gradient mixer, a peek pulse damper, a Model 540 autoinjector, a CoulArray Thermostatic Chamber and a serial array of eight coulometric electrodes (ESA Laboratories, Inc., Chelmsford, Mass., USA).
  • the column is a 3.0 ⁇ 150 mm, 3 ⁇ M, Supelcosil LC-18 (Supelco, Bellefonte, Pa., USA).
  • the mobile phase consists of methanol/1Propanol/1 M ammonium acetate (78:20:2 v:v:v) at a flow rate of 0.8 mL/min.
  • concentrations of delta tocopherol are determined by external standardization using purified solutions of delta tocopherol standards (Sigma Chemicals, St. Louis, Mo., USA).
  • the invention encompasses all variations, combinations, and permutations in which one or more limitations, elements, clauses, descriptive terms, etc., from one or more of the claims or from relevant portions of the description is introduced into another claim.
  • any claim that is dependent on another claim can be modified to include one or more limitations found in any other claim that is dependent on the same base claim.
  • the claims recite a composition, it is to be understood that methods of using the composition for any of the purposes disclosed herein are included, and methods of making the composition according to any of the methods of making disclosed herein or other methods known in the art are included, unless otherwise indicated or unless it would be evident to one of ordinary skill in the art that a contradiction or inconsistency would arise.
  • any of the compositions of the invention can be used for inhibiting the formation, progression, and/or recurrence of adhesions at any of the locations, and/or due to any of the causes discussed herein or known in the art. It is also to be understood that any of the compositions made according to the methods for preparing compositions disclosed herein can be used for inhibiting the formation, progression, and/or recurrence of adhesions at any of the locations, and/or due to any of the causes discussed herein or known in the art. In addition, the invention encompasses compositions made according to any of the methods for preparing compositions disclosed herein.
  • any particular embodiment of the present invention may be explicitly excluded from any one or more of the claims.
  • Any embodiment, element, feature, application, or aspect of the compositions and/or methods of the invention e.g., any amphiphilic entity, any component of an amphiphilic entity, any polymer, any biologically active agent, any surfactant, any dispersion medium, any release-retarding ingredient, any AE nanoparticle or composition comprising any AE nanoparticle, any route or location of administration, any purpose for which a composition is administered, etc.
  • any embodiments in which one or more elements, features, purposes, or aspects are excluded are not set forth explicitly herein.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
US12/517,154 2006-12-01 2007-11-30 Amphiphilic entity nanoparticles Abandoned US20100150994A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/517,154 US20100150994A1 (en) 2006-12-01 2007-11-30 Amphiphilic entity nanoparticles

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87219806P 2006-12-01 2006-12-01
PCT/US2007/086018 WO2008070538A2 (en) 2006-12-01 2007-11-30 Micellar nanoparticles comprising botulinum toxin
US12/517,154 US20100150994A1 (en) 2006-12-01 2007-11-30 Amphiphilic entity nanoparticles

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/086018 A-371-Of-International WO2008070538A2 (en) 2006-12-01 2007-11-30 Micellar nanoparticles comprising botulinum toxin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/182,919 Continuation US9724299B2 (en) 2006-12-01 2014-02-18 Amphiphilic entity nanoparticles

Publications (1)

Publication Number Publication Date
US20100150994A1 true US20100150994A1 (en) 2010-06-17

Family

ID=39492999

Family Applications (5)

Application Number Title Priority Date Filing Date
US12/517,154 Abandoned US20100150994A1 (en) 2006-12-01 2007-11-30 Amphiphilic entity nanoparticles
US14/182,919 Active US9724299B2 (en) 2006-12-01 2014-02-18 Amphiphilic entity nanoparticles
US15/636,927 Active US10285941B2 (en) 2006-12-01 2017-06-29 Amphiphilic entity nanoparticles
US16/379,364 Active US10758485B2 (en) 2006-12-01 2019-04-09 Amphiphilic entity nanoparticles
US17/005,440 Abandoned US20210220271A1 (en) 2006-12-01 2020-08-28 Amphiphilic entity nanoparticles

Family Applications After (4)

Application Number Title Priority Date Filing Date
US14/182,919 Active US9724299B2 (en) 2006-12-01 2014-02-18 Amphiphilic entity nanoparticles
US15/636,927 Active US10285941B2 (en) 2006-12-01 2017-06-29 Amphiphilic entity nanoparticles
US16/379,364 Active US10758485B2 (en) 2006-12-01 2019-04-09 Amphiphilic entity nanoparticles
US17/005,440 Abandoned US20210220271A1 (en) 2006-12-01 2020-08-28 Amphiphilic entity nanoparticles

Country Status (11)

Country Link
US (5) US20100150994A1 (de)
EP (2) EP2099429A2 (de)
JP (2) JP2010528981A (de)
KR (1) KR20090106493A (de)
CN (1) CN101848702B (de)
AU (1) AU2007329579A1 (de)
BR (1) BRPI0719756A2 (de)
CA (1) CA2671447A1 (de)
MX (1) MX2009005727A (de)
SG (1) SG177184A1 (de)
WO (1) WO2008070538A2 (de)

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040202669A1 (en) * 2002-12-27 2004-10-14 O'hagan Derek Immunogenic compositions containing phospholipid
US20090214685A1 (en) * 2008-02-22 2009-08-27 Hunt Terrence J Sustained release poloxamer containing pharmaceutical compositions
US20100172943A1 (en) * 2006-12-01 2010-07-08 Anterios, Inc. Peptide nanoparticles and uses therefor
US20110206739A1 (en) * 2008-03-28 2011-08-25 University Of Massachusetts Compositions and methods for the preparation of nanoemulsions
US20110212157A1 (en) * 2008-06-26 2011-09-01 Anterios, Inc. Dermal delivery
US8168611B1 (en) 2011-09-29 2012-05-01 Chemo S.A. France Compositions, kits and methods for nutrition supplementation
US8183227B1 (en) 2011-07-07 2012-05-22 Chemo S. A. France Compositions, kits and methods for nutrition supplementation
WO2012103037A1 (en) * 2011-01-24 2012-08-02 Anterios, Inc. Oil compositions
WO2012103035A1 (en) * 2011-01-24 2012-08-02 Anterios, Inc. Nanoparticle compositions
WO2013063279A1 (en) * 2011-10-25 2013-05-02 The Trustees Of Princeton University A high-loading nanoparticle-based formulation for water-insoluble steroids
US20140161783A1 (en) * 2007-07-10 2014-06-12 Medy-Tox, Inc. Pharmaceutical Liquid Composition of Botulinum Toxin With Improved Stability
US20140234349A1 (en) * 2011-10-03 2014-08-21 Moreinx Ab Nanoparticles, process for preparation and use thereof as carrier for amphipatic and hydrophobic molecules in fields of medicine including cancer treatment and food related compounds
CN104083340A (zh) * 2014-07-29 2014-10-08 厦门大学 一种包埋维a酸的聚乳酸载药微球的制备方法
WO2015200054A3 (en) * 2014-06-24 2016-03-17 The Trustees Of Princeton University Process for encapsulating soluble biologics, therapeutics, and imaging agents
US9724299B2 (en) 2006-12-01 2017-08-08 Anterios, Inc. Amphiphilic entity nanoparticles
US9737518B2 (en) 2013-04-01 2017-08-22 Pulmatrix Operating Company, Inc. Tiotropium dry powders
US10016451B2 (en) 2007-05-31 2018-07-10 Anterios, Inc. Nucleic acid nanoparticles and uses therefor
WO2018148338A1 (en) * 2017-02-07 2018-08-16 Lars Erik Peters Topical formulations and methods
WO2019113044A1 (en) * 2017-12-07 2019-06-13 Ps Therapies Ltd Topical compositions and methods of use thereof
WO2019140432A1 (en) * 2018-01-15 2019-07-18 Hygieia Health Co., Limited Systems, methods, compositions and devices for personalized nutrition formulation and delivery system
US10532019B2 (en) 2005-12-01 2020-01-14 University Of Massachusetts Lowell Botulinum nanoemulsions
US10722436B2 (en) 2015-08-10 2020-07-28 Mary Kay Inc. Topical compositions
CN111826021A (zh) * 2020-06-12 2020-10-27 西北工业大学深圳研究院 一种基于纳米氢氧化钙的壁画表面聚丙烯酸树脂清除用有机凝胶及其制备方法
US10973890B2 (en) 2016-09-13 2021-04-13 Allergan, Inc. Non-protein clostridial toxin compositions
US11103461B2 (en) 2015-12-22 2021-08-31 The Trustees Of Princeton University Process for encapsulating soluble biologics, therapeutics, and imaging agents
US11311496B2 (en) 2016-11-21 2022-04-26 Eirion Therapeutics, Inc. Transdermal delivery of large agents
US20220192983A1 (en) * 2019-04-19 2022-06-23 Sila S.R.L. Granular product based on arginine
CN114874702A (zh) * 2022-05-27 2022-08-09 广东红日星实业有限公司 一种抛光蜡及其制备方法和应用
US11731099B2 (en) 2018-07-20 2023-08-22 The Trustees Of Princeton University Method for controlling encapsulation efficiency and burst release of water soluble molecules from nanoparticles and microparticles produced by inverse flash nanoprecipitation
US11737981B2 (en) 2017-09-12 2023-08-29 The Trustees Of Princeton University Cellulosic polymer nanoparticles and methods of forming them

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8323666B2 (en) * 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
US8658391B2 (en) * 2006-04-27 2014-02-25 Anterios, Inc. Assessment of the effects of topical administration of chemodenervating pharmaceuticals
US20170361130A9 (en) * 2008-05-23 2017-12-21 Pankaj Modi Stabilized and solubilized drug formulation for topical application and transdermal efficacy for cosmetic improvement and methods of formulation
WO2009149083A2 (en) * 2008-06-03 2009-12-10 University Of Maryland, Baltimore Non-hemolytic clya for excretion of proteins
CN102202672A (zh) * 2008-10-10 2011-09-28 达拉生物科学公司 使用穗霉素衍生物治疗或预防疼痛的方法
WO2010102066A1 (en) 2009-03-05 2010-09-10 Bend Research, Inc. Dextran polymer powder for inhalation administration of pharmaceuticals
AU2010265888A1 (en) 2009-06-25 2012-01-19 Revance Therapeutics, Inc. Albumin-free botulinum toxin formulations
US8147848B2 (en) 2009-08-26 2012-04-03 Allergan, Inc. Method for treating premature ejaculation with a botulinum neurotoxin
US8888736B2 (en) 2010-04-30 2014-11-18 H R D Corporation High shear application in medical therapy
EP2563338A4 (de) * 2010-04-30 2014-06-18 H R D Corp Anwendung mit hoher scherung für eine medikamentenabgabe
US20120189677A1 (en) * 2011-01-20 2012-07-26 Stephen Tonge Formulations
KR20190014125A (ko) * 2011-01-24 2019-02-11 안테리오스, 인코퍼레이티드 나노입자 조성물, 이의 제형, 및 그의 용도
WO2012103039A1 (en) * 2011-01-24 2012-08-02 Anterios, Inc. Surfactant compositions
CO6540157A1 (es) 2011-04-15 2012-10-16 Univ Antioquia Proceso continuo para la elaboracion de nanoparticulas y nanoparticulas obtenidas mediante dicho proceso
TWI458504B (zh) * 2011-05-02 2014-11-01 Univ Nat Cheng Kung 經皮藥物釋放貼片及利用近紅外光控制其藥物釋放之方法
US9060938B2 (en) 2011-05-10 2015-06-23 Bend Research, Inc. Pharmaceutical compositions of active agents and cationic dextran polymer derivatives
GB201208384D0 (en) * 2012-05-14 2012-06-27 Sequessome Technology Holdings Ltd Vesicular formulations, uses and methods
US20140322428A1 (en) 2013-03-15 2014-10-30 Leading Edge Innovations, LLC Compositions having an oil-in-water dispersion of submicron particles to enhance foods and beverages
IL225985A0 (en) * 2013-04-25 2013-07-31 Dov Ingman Prof Preparation@cosmetic@mushkollal
MX339086B (es) 2013-06-20 2016-05-09 Inmolecule Internat Ltd Nanomaterial de dioxido de titanio nanoparticulado modificado con grupos funcionales y con extractos citricos adsorbidos en la superficie para la eliminacion de amplio espectro de microorganismos.
CA2961746A1 (en) * 2014-09-17 2016-03-24 Vivacelle Bio, Inc. Stable micelle and/or liposome compositions and uses thereof
WO2019113184A1 (en) * 2017-12-06 2019-06-13 Children's Medical Center Corporation Nanoparticles for nerve penetration and uses thereof
MX2021002995A (es) 2018-09-13 2021-07-15 Eirion Therapeutics Inc Inhibidores del inhibidor 1 de activador de plasminogeno (pai-1) y usos de los mismos.
WO2020056191A1 (en) 2018-09-13 2020-03-19 Eirion Therapeutics, Inc. Uses of plasminogen activator inhibitor 1 (pai-1) inhibitors
CN109833295A (zh) * 2018-10-25 2019-06-04 安徽医科大学 一种肿瘤靶向和pH响应的聚合物胶束及其制备方法
EP3934616A1 (de) * 2019-03-06 2022-01-12 Isdin, S. A. Verwendung von capryl- und caprin-triglyceriden zur behandlung von krankheiten oder zuständen, die durch filaggrin oder kollagenmangel vermittelt werden
CN110637814B (zh) * 2019-10-22 2021-11-19 青海省畜牧兽医科学院 一种d型肉毒毒素的微囊化制备方法
CN115135309B (zh) * 2019-11-15 2024-04-12 B.A.I.实验室有限责任公司 透皮递送系统
US20240050538A1 (en) * 2020-12-18 2024-02-15 Atgc Co., Ltd. Pharmaceutical composition for long-term storage of liquid formulation of botulinum toxin
BR102021015486A2 (pt) * 2021-08-05 2023-02-14 Aché Laboratórios Farmacêuticos S.A. Composição de nanopartícula lipídica contendo extrato de vitis vinifera, usos cosméticos de uma composição de nanopartícula lipídica contendo extrato de vitis vinifera, produto dermocosmético antioxidante e para prevenir o envelhecimento da pele e método de cuidado da pele
PE20220306A1 (es) * 2021-12-22 2022-03-09 Univ San Ignacio De Loyola S A Jabon unidosis en polvo compactado de rapida disolucion en el tiempo necesario para asegurar limpieza de manos con efecto hidratante
CN114951680B (zh) * 2022-05-17 2023-07-14 徐州工程学院 一种具有生物沉默区拉曼信号的双配体金纳米粒子的合成方法和应用
FR3144515A1 (fr) * 2022-12-29 2024-07-05 Lvmh Recherche Composition cosmétique comprenant du pullulan et des liposomes véhiculant un actif hydrophile

Citations (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4533254A (en) * 1981-04-17 1985-08-06 Biotechnology Development Corporation Apparatus for forming emulsions
US4908154A (en) * 1981-04-17 1990-03-13 Biotechnology Development Corporation Method of forming a microemulsion
US5008110A (en) * 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5401243A (en) * 1990-08-21 1995-03-28 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
US5502045A (en) * 1991-05-03 1996-03-26 Raision Tehtaat Oy Ab Use of a stanol fatty acid ester for reducing serum cholesterol level
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5591767A (en) * 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5629021A (en) * 1995-01-31 1997-05-13 Novavax, Inc. Micellar nanoparticles
US5651991A (en) * 1987-10-28 1997-07-29 Nippon Shinyaku Co. Ltd. Drug carriers
US5652274A (en) * 1991-03-01 1997-07-29 Martin; Alain Therapeutic-wound healing compositions and methods for preparing and using same
US5660858A (en) * 1996-04-03 1997-08-26 Research Triangle Pharmaceuticals Cyclosporin emulsions
US5753241A (en) * 1995-02-27 1998-05-19 L'oreal Transparent nanoemulsion less than 100 NM based on fluid non-ionic amphiphilic lipids and use in cosmetic or in dermopharmaceuticals
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
US5858410A (en) * 1994-11-11 1999-01-12 Medac Gesellschaft Fur Klinische Spezialpraparate Pharmaceutical nanosuspensions for medicament administration as systems with increased saturation solubility and rate of solution
US5925341A (en) * 1997-03-18 1999-07-20 L'oreal Nanoemulsion based on nonionic amphiphilic lipids and aminated silicones and uses
US5932562A (en) * 1998-05-26 1999-08-03 Washington University Sitostanol formulation to reduce cholesterol absorption and method for preparing and use of same
US6010715A (en) * 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
US6039936A (en) * 1996-11-15 2000-03-21 L'oreal Nanoemulsion based on non-ionic and cationic amphiphilic lipids and uses thereof
US6224853B1 (en) * 1997-04-22 2001-05-01 Woolcombers Group Plc Aqueous compositions comprising a lipid and a lanolin-derived surfactant, and their use
US6265180B1 (en) * 1998-03-30 2001-07-24 Mibelle Ag Cosmetics Nanoemulsions for delivering lipophilic substances into cells
US6274150B1 (en) * 1998-12-23 2001-08-14 L'oreal Nanoemulsion based on phosphoric acid fatty acid esters and its uses in the cosmetics, dermatological, pharmaceutical, and/or ophthalmological fields
US20020015721A1 (en) * 1999-01-05 2002-02-07 Jean-Thierry Simonnet Nanoemulsion based on ethylene oxide and propylene oxide block copolymers and its uses in the cosmetics, dermatological and/or ophthalmological fields
US6358917B1 (en) * 1999-08-24 2002-03-19 Jean D. A. Carruthers Cosmetic use of botulinum toxin for treatment of downturned mouth
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
US6387411B2 (en) * 1998-11-30 2002-05-14 Mcneil-Ppc, Inc. Method for producing dispersible sterol and stanol compounds
US20020098215A1 (en) * 2000-01-21 2002-07-25 Veronique Douin Nanoemulsions comprising at least one amphiphilic lipid, at least one oil, and at least one nonionic polymer, and uses thereof
US6429189B1 (en) * 1999-12-10 2002-08-06 Botulinum Toxin Research Associates, Inc. Cytotoxin (non-neurotoxin) for the treatment of human headache disorders and inflammatory diseases
US20020107199A1 (en) * 2000-12-05 2002-08-08 Allergan Sales, Inc. Methods of administering botulinum toxin
US20030072801A1 (en) * 2001-06-22 2003-04-17 Pfizer Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
US20030077240A1 (en) * 2001-10-24 2003-04-24 Clariant International, Ltd. Use of high-purity phenylsilsesquioxane liquids for the preparation of cosmetic and pharmaceutical compositions
US20030086888A1 (en) * 2001-10-24 2003-05-08 Clariant International, Ltd Leave-on compositions for personal care
US6573241B1 (en) * 1998-12-10 2003-06-03 BioteCon Gesellschaft für bio-technologische Entwicklung und Consulting GmbH Therapeutic agent for the suppression of snoring noises
US20030108597A1 (en) * 2001-08-13 2003-06-12 Chancellor Michael B. Application of lipid vehicles and use for drug delivery
US6589588B1 (en) * 1998-05-06 2003-07-08 Raisio Benecol Oy Phytosterol compositions
US20030157138A1 (en) * 2000-01-10 2003-08-21 Meir Eini Dermatological application with solidified fat compositions
US20040003324A1 (en) * 2002-06-29 2004-01-01 Richard Uhlig Handling faults associated with operation of guest software in the virtual-machine architecture
US20040009936A1 (en) * 1999-05-03 2004-01-15 Tang De-Chu C. Vaccine and drug delivery by topical application of vectors and vector extracts
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
US6688311B2 (en) * 2002-03-14 2004-02-10 Allergan, Inc. Method for determining effect of a clostridial toxin upon a muscle
US20040028635A1 (en) * 2000-11-17 2004-02-12 Cedric Chauvierre Block-structure copolymer consisting of a saccharide segment bound to at least a biodegradable hydrophobic segment, and corresponding particles
US20040033202A1 (en) * 2002-06-10 2004-02-19 Elan Pharma International, Ltd. Nanoparticulate sterol formulations and novel sterol combinations
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US20040037853A1 (en) * 2002-05-28 2004-02-26 Gary Borodic Composition for therapeutic and cosmetic botulinum toxin
US20040048836A1 (en) * 2001-03-23 2004-03-11 Wilmott James M Method for preparing high pressure/ high shear dispersions containing physiologically active ingredients
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US20040081688A1 (en) * 2000-12-27 2004-04-29 Del Curto Maria Dorly Amphiphilic lipid nanoparticles for peptide and/or protein incorporation
US20040115159A1 (en) * 2002-03-29 2004-06-17 Tadlock Charles C Novel nanoemulsions
US20040115727A1 (en) * 2002-12-11 2004-06-17 Allergan, Inc., A Corporation Evolved clostridial toxins with altered protease specificity
US20040127661A1 (en) * 2002-09-12 2004-07-01 Harald Kaspar Fluoroelastomers having low temperature characteristics and solvent resistance
US20040126397A1 (en) * 1993-12-28 2004-07-01 Allergan, Inc. Use of the neurotoxic component of a botulinum toxin for treating various disorders and conditions and associated pain
US20040132667A1 (en) * 2003-11-17 2004-07-08 Sederma S.A.S Compositions containing mixtures of tetrapeptides and tripeptides
US20040151741A1 (en) * 2002-12-20 2004-08-05 Gary Borodic Pharmaceutical botulinum toxin compositions
WO2004076634A2 (en) * 2003-02-24 2004-09-10 Ira Sanders Cell membrane translocation of regulated snare inhibitors , compositions therefor, and methods for treatment of disease
US20050005370A1 (en) * 2003-07-07 2005-01-13 The Procter & Gamble Company 2-(Amino or substituted amino)-5-(substituted oxymethyl)-phenol compounds, dyeing compositions containing them, and use thereof
US20050038096A1 (en) * 2003-08-13 2005-02-17 The University Of Houston Parenteral and oral formulations of benzimidazoles
US6861066B2 (en) * 2002-03-11 2005-03-01 Health Plus International Inc. Method for the delivery of a biologically active agent
US20050048088A1 (en) * 2003-08-28 2005-03-03 Fred Zulli Compositions comprising at least two nanoemulsions
US6869610B2 (en) * 2000-04-14 2005-03-22 Allergan Sales, Inc. Pain treatment by peripheral administration of a neurotoxin
US20050065090A1 (en) * 2001-10-30 2005-03-24 Christian Ludin Dermopharmaceutically and cosmetically active oligopeptides
US20050074466A1 (en) * 2001-07-27 2005-04-07 Suskind Dana L. Botulinum toxin in the treatment or prevention of acne
US20050079131A1 (en) * 2003-08-08 2005-04-14 Lanza Gregory M. Emulsion particles for imaging and therapy and methods of use thereof
US20050079228A1 (en) * 2003-05-30 2005-04-14 Ashish Jaiswal Clear, stable topical compositions of clarithromycin and processes for their preparation
US20050096340A1 (en) * 2003-10-29 2005-05-05 Yuehua Zhang Tocopherol-modified therapeutic drug compounds
US6890560B2 (en) * 2001-06-25 2005-05-10 Samyang Corporation Negatively charged amphiphilic block copolymer as drug carrier
US20050118254A1 (en) * 2001-12-27 2005-06-02 Choi Jae M. Microemulsion preconcentrate
US6902737B2 (en) * 2001-01-18 2005-06-07 L'oreal Translucent nanoemulsion, production method, and uses thereof in the cosmetic, dermatological and/or ophthalmological fields
US20050124378A1 (en) * 1999-12-29 2005-06-09 Bellsouth Intellectual Property Corporation Portable communications device coupled to first network by way of second network
US20050123897A1 (en) * 1999-07-05 2005-06-09 Idea Ag Method for the improvement of transport across adaptable semi-permeable barriers
US20050136024A1 (en) * 2003-12-22 2005-06-23 Stockel Richard F. Dermatological compositions
US20050142150A1 (en) * 1991-09-24 2005-06-30 Allergan, Inc. Botulinum toxin formulations
US20060018931A1 (en) * 2004-07-26 2006-01-26 Taylor Harold V Therapeutic composition with a botulinum neurotoxin
US7001602B2 (en) * 1997-07-15 2006-02-21 The Regents Of The University Of Colorado Use of botulinum toxin therapy for urinary incontinence and related disorders
US20060073208A1 (en) * 2004-10-01 2006-04-06 Allergan, Inc. Cosmetic neurotoxin compositions and methods
US20060084353A1 (en) * 2004-10-18 2006-04-20 Wong Tak K Reversible ball having hyper-elastic properties
US20060093624A1 (en) * 1991-09-24 2006-05-04 Allergan, Inc. Botulinum toxin for treating muscle contracture
US20060153877A1 (en) * 2003-06-20 2006-07-13 Shunji Kozaki Remedies for dissease with hypermyotonia
US20060165657A1 (en) * 2003-02-05 2006-07-27 Paul Bernasconi Method for delivery of cosmetic by topical application
US20060182794A1 (en) * 2005-02-14 2006-08-17 Pankaj Modi Stabilized compositions for topical administration and methods of making same
US20070009555A1 (en) * 2005-06-14 2007-01-11 Borodic Gary E Botulinum toxin and the treatment of primary disorders of mood and affect
US20070036831A1 (en) * 2005-08-09 2007-02-15 Nanobio Corporation Nanoemulsion compositions having anti-inflammatory activity
US20070104743A1 (en) * 2005-11-09 2007-05-10 Hormos Medical Ltd. Formulations of fispemifene
US20070116723A1 (en) * 2001-12-18 2007-05-24 Coleman William P Iii Topically applied clostridium botulinum toxin compositions and treatment methods
US7228259B2 (en) * 2004-06-30 2007-06-05 Lucent Technologies Inc. Method and apparatus for structure-preserving reduced-order modeling
US20070148194A1 (en) * 2005-11-29 2007-06-28 Amiji Mansoor M Novel nanoemulsion formulations
US20080050352A1 (en) * 2004-07-12 2008-02-28 Paul Webb Pharmaceutical Composition Comprising Botulinum, a Non Ionic Surfactant, Sodium Chloride and Sucrose
US20090041680A1 (en) * 2007-08-07 2009-02-12 Foamix Ltd. Wax Foamable Vehicle and Pharmaceutical Compositions Thereof
US20100040883A1 (en) * 2001-12-19 2010-02-18 Mccarthy Stephen P Polysaccharide-containing block copolymer particles and uses thereof
US20100172943A1 (en) * 2006-12-01 2010-07-08 Anterios, Inc. Peptide nanoparticles and uses therefor
US20100183726A1 (en) * 2006-08-02 2010-07-22 Robert Nicolosi Compositions and methods for treating cancer with dacarbazine nanoemulsions
US20120164182A1 (en) * 2005-12-01 2012-06-28 University Of Massachusetts Botulinum nanoemulsions

Family Cites Families (169)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US296006A (en) 1884-04-01 John hoefleb
US3725540A (en) 1970-07-30 1973-04-03 Procter & Gamble Color and odor stabilized dry aerosol antiperspirant
US4172149A (en) 1978-01-30 1979-10-23 Westwood Pharmaceuticals, Inc. Method for treating living skin exhibiting excessive sebum secretion
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
CA1283827C (en) 1986-12-18 1991-05-07 Giorgio Cirelli Appliance for injection of liquid formulations
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
JPH0798740B2 (ja) 1987-10-28 1995-10-25 日本新薬株式会社 薬物担体
IL88076A (en) 1987-10-28 1993-01-14 Nippon Shinyaku Co Ltd Fat emulsions as drug carriers
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
CH677886A5 (de) 1989-06-26 1991-07-15 Hans Georg Prof Dr Weder
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
WO1992003122A1 (de) 1990-08-24 1992-03-05 Gregor Cevc Präparat zur wirkstoffapplikation in kleinsttröpfchenform
US6165500A (en) 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
US6939852B2 (en) 1991-09-24 2005-09-06 Allergan, Inc. Methods and compositions for the treatment of cerebral palsy
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
IL101387A (en) 1992-03-26 1999-11-30 Pharmos Ltd Emulsion with enhanced topical and/or transdermal systemic effect utilizing submicron oil droplets
EP0572080B1 (de) 1992-05-29 1995-11-15 Quest International B.V. Parfümöl enthaltende wässrige Mikroemulsionen
EP0571677A1 (de) 1992-05-29 1993-12-01 Unilever Plc Parfümöle enthaltende wässrige Mikroemulsionen
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
CA2091152C (en) 1993-03-05 2005-05-03 Kirsten Westesen Solid lipid particles, particles of bioactive agents and methods for the manfuacture and use thereof
US5576016A (en) 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
US5470577A (en) 1993-07-07 1995-11-28 Trustees Of Boston University Stimulation of tanning by DNA fragments or single-stranded DNA
IT1261849B (it) 1993-09-02 1996-06-03 Avantgarde Spa Dispositivo medico per la somministrazione di principi attivi o farmaci a bassissimo dosaggio, in particolare di farmaci omeopatici.
US6974578B1 (en) 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
HUT74735A (en) 1994-02-25 1997-02-28 Takeda Chemical Industries Ltd Injectable emulsion composition containing antifungal triazole derivatives and process for producing it
JPH07285863A (ja) 1994-02-25 1995-10-31 Takeda Chem Ind Ltd 注射剤組成物およびその製造方法
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
US5670484A (en) 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
ES2078190B1 (es) 1994-05-20 1996-08-01 Cusi Lab Procedimiento para el recubrimiento de goticulas o particulas de tamaño nanometrico.
DE69528062T2 (de) 1994-06-20 2003-04-30 Nippon Shinyaku Co., Ltd. Verfahren zum herstellen von emulsionen aus einem emulgator
US5672358A (en) 1994-06-21 1997-09-30 Ascent Pharmaceuticals, Inc. Controlled release aqueous emulsion
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
ES2198484T3 (es) 1995-06-06 2004-02-01 L. Bruce Pearce Composiciones y procedimientos mejorados para quimiodenervacion usando neurotoxinas.
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
EP1921902B1 (de) 1996-12-19 2011-03-02 Ibiden Co., Ltd. Mehrlagige Leiterplatte
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US5994414A (en) 1997-04-28 1999-11-30 Avon Products, Inc. Water-thin emulsion formed by high pressure homogenization process
EP1027033B1 (de) 1997-05-14 2009-07-22 The University Of British Columbia Hochwirksame verkapselung von nukleinsäuren in lipidvesikeln
US6835395B1 (en) 1997-05-14 2004-12-28 The University Of British Columbia Composition containing small multilamellar oligodeoxynucleotide-containing lipid vesicles
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
US6007856A (en) 1997-08-08 1999-12-28 The Procter & Gamble Company Oil-in-water dispersions of β-carotene and other carotenoids stable against oxidation prepared from water-dispersible beadlets having high concentrations of carotenoid
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
EP1080720A4 (de) 1998-03-05 2002-06-05 Nippon Shinyaku Co Ltd Fettemulsionen zur inhalativen verabreichung
US5965154A (en) 1998-03-17 1999-10-12 Plc Holding, L.L.C. Adhesive matrix type transdermal patch and method of manufacturing same
GB9817052D0 (en) * 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
FR2783169B1 (fr) 1998-09-15 2001-11-02 Sederma Sa Utilisation cosmetique ou dermopharmaceutique de peptides pour la cicatrisation et pour l'amelioration de l'aspect cutane lors du vieillissement naturel ou accelere (heliodermie, pollution)
ES2226203T3 (es) 1998-12-23 2005-03-16 Idea Ag Formulacion mejorada para aplicacion topica no invasiva.
US20030229141A1 (en) * 1999-01-08 2003-12-11 Yu Ruey J. N-acetyl cysteine and its topical use
US6635676B2 (en) 1999-04-28 2003-10-21 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
IL146567A0 (en) 1999-06-04 2002-07-25 Skyepharma Inc Oil-core particles containing a hydrophobic core material and hydrophobic drug and method for the preparation thereof
JP2003506398A (ja) 1999-08-04 2003-02-18 イデア アクチェンゲゼルシャフト 脂質、高分子電解質、及び構造誘導性可溶性低原子価リンカーを含む周期的構造、並びにその生物学的使用方法
US7838008B2 (en) 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
JP4215429B2 (ja) * 1999-12-28 2009-01-28 バイオニケ ライフ サイエンシーズ インコーポレイテッド 癌治療におけるヒアルロン酸
AU2001245947A1 (en) 2000-03-23 2001-10-03 Collaborative Technologies, Inc Method for preparing high pressure/high shear dispersions containing physiologically active ingredients
US6471968B1 (en) 2000-05-12 2002-10-29 Regents Of The University Of Michigan Multifunctional nanodevice platform
FR2809112B1 (fr) 2000-05-16 2004-05-07 Centre Nat Rech Scient Materiaux a base de polymeres biodegradables et son procede de preparation
FR2809010B1 (fr) 2000-05-22 2002-07-12 Oreal Nanoemulsion a base de polymeres anioniques, et ses utilisations notamment dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
US6670322B2 (en) 2000-06-01 2003-12-30 Wisconsin Alumni Research Foundation Method of targeting pharmaceuticals to motor neurons
US20020155084A1 (en) 2000-06-02 2002-10-24 The Regents Of The University Of The Michigan Nanoemulsion formulations
US6306423B1 (en) * 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
FR2811561B1 (fr) 2000-07-13 2003-03-21 Oreal Composition, notamment cosmetique, renfermant la dhea et/ou un precurseur ou derive chimique ou biologique de celle-ci, et un inhibiteur de metalloproteinase
US20040220100A1 (en) 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
US6455058B1 (en) 2000-09-13 2002-09-24 Amitee Cosmetics, Inc. Composition and method for hair and scalp treatment
FI20010115A0 (fi) 2001-01-18 2001-01-18 Orion Corp Menetelmä nanopartikkelien valmistamiseksi
CA2442660A1 (en) 2001-03-30 2002-10-17 Color Access, Inc. Novel nanoemulsions
KR100463167B1 (ko) 2001-04-13 2004-12-23 주식회사 태평양 고분자 나노입자를 이용한 경피흡수제 및 이를 함유한외용제 조성물
AU2002367976B2 (en) 2001-06-05 2007-06-21 The Regents Of The University Of Michigan Nanoemulsion vaccines
DE10146647A1 (de) 2001-09-21 2003-04-24 Marc Heckmann Arzneimittel zur Prophylaxe und Therapie von Bromhidrosis
US6765001B2 (en) 2001-12-21 2004-07-20 Medicis Pharmaceutical Corporation Compositions and methods for enhancing corticosteroid delivery
EP1334729A1 (de) 2002-02-07 2003-08-13 Botulinum Toxin Research Associates, Inc. Therapeutische Verwendung des nicht-neurotoxischen Clostridium Botulinum Toxins Typ C2
US6623780B1 (en) 2002-03-26 2003-09-23 Cargill, Inc. Aqueous dispersible sterol product
AU2003231082A1 (en) 2002-05-02 2003-11-17 Pr Pharmaceuticals, Inc. Controlled release compositions of estradiol metabolites
US7691394B2 (en) 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
WO2003101483A1 (en) * 2002-05-31 2003-12-11 Solux Corporation Pharmaceutical preparation of botulinum neurotoxin, methods of synthesis and methods of clinical use
JP2005532355A (ja) 2002-06-11 2005-10-27 エティファルム ステルス脂質ナノカプセル、その製造方法、およびその、活性要素用キャリヤーとしての使用
US20070292359A1 (en) 2002-10-25 2007-12-20 Foamix Ltd. Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US7476393B2 (en) 2002-11-29 2009-01-13 L'oreal Process for the preparation of a cationic nanoemulsion, and cosmetic composition
DE10258960A1 (de) 2002-12-16 2004-07-01 Henkel Kgaa Nanoskalige Hydrogele gegen Falten, raue und trockene Haut
FR2849375B1 (fr) 2002-12-30 2006-10-20 Jean Noel Thorel Compositions cosmetiques, par exemple pour traiter le vieillissement cutane photo-induit
EP1587499A1 (de) 2003-01-31 2005-10-26 Elan Pharma International Limited Nanopartikuläre topiramat formulierung
US8512727B2 (en) 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
US20040247623A1 (en) * 2003-03-24 2004-12-09 Roger Cady Method and article for treatment of sensory neuron related disorders through transdermal application of botulinum toxin
US20040191330A1 (en) 2003-03-31 2004-09-30 Keefe Candace R. Daily skin care regimen
WO2004087203A2 (en) 2003-04-02 2004-10-14 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations for topical application
GB0312309D0 (en) 2003-05-29 2003-07-02 Gaslini Children S Hospital G Targeted liposome
AU2004273779B2 (en) 2003-06-04 2009-10-22 Nanobio Corporation Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof
US20050208083A1 (en) 2003-06-04 2005-09-22 Nanobio Corporation Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof
CA2529953A1 (en) * 2003-06-23 2004-12-29 Transpharma Medical Ltd. Transdermal delivery system for cosmetic agents
CA2534471A1 (en) 2003-08-06 2005-02-17 Eisai Co., Ltd. Method and apparatus for producing ultrafine drug particles
EP1510206A1 (de) 2003-08-29 2005-03-02 Novagali Pharma SA Selbstnanoemulgierende ölige Formulierung zur Verabreichung wasserschwerlöslicher Wirkstoffe
JP2006199589A (ja) 2003-09-03 2006-08-03 Ltt Bio-Pharma Co Ltd 生理活性タンパク質またはペプチドを含有するナノ粒子およびその製造方法、ならびに当該ナノ粒子からなる外用剤
EP1706155A4 (de) * 2003-12-17 2009-08-05 Smithkline Beecham Corp Polymere micellenkomplexe und vehikel davon zur arzneistoffzuführung
NO20035681D0 (no) 2003-12-18 2003-12-18 Amersham Health As Optisk avbildning av lungekreft
EP1547674A1 (de) 2003-12-23 2005-06-29 MediGene Oncology GmbH Verfahren zur Herstellung von Kolloidteilchen
US6974579B2 (en) 2004-01-08 2005-12-13 Allergan, Inc. Methods for treating vascular disorders
FR2865131B1 (fr) 2004-01-15 2007-08-24 Gattefosse Ets Sa Utilisation d'un extrait d'acmella oleracea pour son effet botox like dans une composition cosmetique anti-rides
WO2005070394A2 (en) 2004-01-23 2005-08-04 Camurus Ab Ternary non-lamellar lipid compositions
US20050196416A1 (en) * 2004-02-05 2005-09-08 Kipp James E. Dispersions prepared by use of self-stabilizing agents
CN1917772A (zh) 2004-02-23 2007-02-21 得克萨斯A&M大学系统 抗氧化组合物及其使用方法
DE102004009287A1 (de) 2004-02-26 2005-09-15 Institut Für Neue Materialien Gem. Gmbh Amphiphile Nanopartikel
WO2005084410A2 (en) 2004-03-03 2005-09-15 Essentia Biosystems, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US20050214325A1 (en) 2004-03-26 2005-09-29 Vvii Newco 2003, Inc. Compositions and methods to increase the effect of a neurotoxin treatment
AU2005226649B2 (en) 2004-03-22 2010-04-29 Celgene Corporation Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders
DE102004016710B4 (de) 2004-04-05 2020-11-19 Greppmayr GmbH Formulierung zur Fußpflege
EP1586336A1 (de) 2004-04-06 2005-10-19 JOHNSON & JOHNSON GmbH Zusammensetzung enthaltend Kupfer und Sojaprodukte
TW200603843A (en) 2004-04-20 2006-02-01 Technology Dev Company Ltd Tissue enhancement implant and method
US20050249686A1 (en) 2004-04-27 2005-11-10 Francoise Pataut Cosmetic composition free of water comprising fatty acid esters, petrolatum oil and non-ionic polymers
US7591806B2 (en) 2004-05-18 2009-09-22 Bai Xu High-aspect-ratio microdevices and methods for transdermal delivery and sampling of active substances
KR100623013B1 (ko) 2004-09-04 2006-09-19 김영대 나노에멀션, 그의 용도 및 제조방법
US20060057165A1 (en) * 2004-09-10 2006-03-16 Dimitrios Dimitrakoudis Clostridium botulinum toxin formulation and method for reducing weight
CA2584475A1 (en) 2004-11-12 2006-05-18 Idea Ag Extended surface aggregates in the treatment of skin conditions
EP1848407A2 (de) 2005-02-02 2007-10-31 Mega Lifesciences Pvt. Ltd. Orale pharmazeutische zusammensetzung
CA2494473C (en) 2005-02-14 2007-06-26 Dpm Therapeutics Corp. Stabilized protein compositions for topical administration and methods of making same
PT1853303E (pt) * 2005-02-14 2016-03-23 Dpm Therapeutics Corp Composições estabilizadas para administração tópica, e métodos para a sua preparação
US20080220021A1 (en) 2005-02-14 2008-09-11 Pankaj Modi Topical Botulinum Toxin Compositions for the Treatment of Hyperhidrosis
BRPI0608249A2 (pt) * 2005-03-03 2009-12-08 Revance Therapeutics Inc formulação, método para aplicação tópica e kit para distribuição transdérmica de toxina botulìnica
JP4444149B2 (ja) * 2005-03-30 2010-03-31 株式会社ナリス化粧品 超微細エマルジョンで構成される皮膚外用剤
CA2948238A1 (en) * 2005-06-14 2006-12-28 Revance Therapeutics, Inc. Botulinum toxin and the treatment of primary disorders of mood and affect
CN103315954A (zh) 2005-07-18 2013-09-25 麻萨诸塞州洛厄尔大学 制备与使用纳米乳剂的组合物和方法
US20090306198A1 (en) 2005-09-16 2009-12-10 Robert Nicolosi Anti-Oxidant Synergy Formulation Nanoemulsions to Treat Caner
US8137677B2 (en) 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
DE102006046076A1 (de) 2005-10-14 2007-04-19 Henkel Kgaa Kosmetische und dermatologische Zusammensetzungen mit Oligopeptiden und Apfelextrakt
CN101340884A (zh) 2005-10-19 2009-01-07 曼尼·马纳舍·辛格尔 用于治疗多汗症的方法
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
US20070178121A1 (en) 2006-01-27 2007-08-02 Allergan, Inc. Methods for enhancing skin treatments
CA2645073A1 (en) 2006-03-08 2007-09-13 Nuviance, Inc. Transdermal drug delivery compositions and topical compositions for application on the skin
US8658391B2 (en) 2006-04-27 2014-02-25 Anterios, Inc. Assessment of the effects of topical administration of chemodenervating pharmaceuticals
WO2007149868A2 (en) 2006-06-20 2007-12-27 The Regents Of The University Of California Controlled release encapsulated anti-bacterial and anti-inflammatory nanoparticles
WO2008038147A2 (en) 2006-07-05 2008-04-03 Foamix Ltd. Foamable vehicle comprising dicarboxylic acid or dicarboxylic acid ester and pharmaceutical compositions thereof
US7445783B2 (en) * 2006-10-30 2008-11-04 Cappellos, Inc. Topical and transdermal treatments using urea formulations
US20080206155A1 (en) 2006-11-14 2008-08-28 Foamix Ltd. Stable non-alcoholic foamable pharmaceutical emulsion compositions with an unctuous emollient and their uses
CA2671447A1 (en) 2006-12-01 2008-06-12 Anterios, Inc. Amphiphilic entity nanoparticles
CA2672973C (en) 2006-12-21 2016-03-08 Novagali Pharma Sa Process for manufacturing ophthalmic oil-in-water emulsions
EP1938801A1 (de) 2006-12-22 2008-07-02 Biofrontera Bioscience GmbH Nanoemulsion
WO2008151022A2 (en) 2007-05-31 2008-12-11 Anterios, Inc. Nucleic acid nanoparticles and uses therefor
AU2008314647B2 (en) 2007-10-12 2013-03-21 Massachusetts Institute Of Technology Vaccine nanotechnology
CA2719803A1 (en) 2008-03-28 2009-10-01 University Of Massachusetts Compositions and methods for the preparation of nanoemulsions
BRPI0914630A2 (pt) 2008-06-26 2019-09-24 Anterios Inc liberação dérmica
WO2010036652A1 (en) 2008-09-23 2010-04-01 Thomas Jefferson University Cancer vaccines against mucosal antigens and methods of making and using the same
US20100137357A1 (en) 2008-11-26 2010-06-03 Koleng John J Compositions and methods for hyperhidrosis
US20100226983A1 (en) 2009-01-28 2010-09-09 Nanobio Corporation Compositions for treatment and prevention of acne, methods of making the compositions, and methods of use thereof
WO2012103035A1 (en) 2011-01-24 2012-08-02 Anterios, Inc. Nanoparticle compositions
JP6131194B2 (ja) 2011-01-24 2017-05-17 アンテリオス， インコーポレイテッド 皮膚科学的症状を処置するためのエンプティナノ粒子組成物およびその使用
EP2667897A1 (de) 2011-01-24 2013-12-04 Anterios, Inc. Parabenzusammensetzungen
EP2667945A1 (de) 2011-01-24 2013-12-04 Anterios, Inc. Ölzusammensetzungen
KR20190014125A (ko) 2011-01-24 2019-02-11 안테리오스, 인코퍼레이티드 나노입자 조성물, 이의 제형, 및 그의 용도
WO2012103039A1 (en) 2011-01-24 2012-08-02 Anterios, Inc. Surfactant compositions
AU2015252949B2 (en) 2014-05-01 2020-12-10 Anterios, Inc. Methods to treat, prevent, and improve skin conditions
US10485855B2 (en) 2014-05-01 2019-11-26 Anterios, Inc. Demonstrable efficacy across or within patient populations

Patent Citations (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4908154A (en) * 1981-04-17 1990-03-13 Biotechnology Development Corporation Method of forming a microemulsion
US4533254A (en) * 1981-04-17 1985-08-06 Biotechnology Development Corporation Apparatus for forming emulsions
US5651991A (en) * 1987-10-28 1997-07-29 Nippon Shinyaku Co. Ltd. Drug carriers
US5008110A (en) * 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5401243A (en) * 1990-08-21 1995-03-28 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
US5652274A (en) * 1991-03-01 1997-07-29 Martin; Alain Therapeutic-wound healing compositions and methods for preparing and using same
US5502045A (en) * 1991-05-03 1996-03-26 Raision Tehtaat Oy Ab Use of a stanol fatty acid ester for reducing serum cholesterol level
US20050142150A1 (en) * 1991-09-24 2005-06-30 Allergan, Inc. Botulinum toxin formulations
US20060093624A1 (en) * 1991-09-24 2006-05-04 Allergan, Inc. Botulinum toxin for treating muscle contracture
US7384918B2 (en) * 1991-09-24 2008-06-10 Allergan, Inc. Botulinum toxin for treating muscle contracture
US6010715A (en) * 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
US5591767A (en) * 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US20040126397A1 (en) * 1993-12-28 2004-07-01 Allergan, Inc. Use of the neurotoxic component of a botulinum toxin for treating various disorders and conditions and associated pain
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
US5858410A (en) * 1994-11-11 1999-01-12 Medac Gesellschaft Fur Klinische Spezialpraparate Pharmaceutical nanosuspensions for medicament administration as systems with increased saturation solubility and rate of solution
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
US5629021A (en) * 1995-01-31 1997-05-13 Novavax, Inc. Micellar nanoparticles
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5753241A (en) * 1995-02-27 1998-05-19 L'oreal Transparent nanoemulsion less than 100 NM based on fluid non-ionic amphiphilic lipids and use in cosmetic or in dermopharmaceuticals
US5660858A (en) * 1996-04-03 1997-08-26 Research Triangle Pharmaceuticals Cyclosporin emulsions
US6039936A (en) * 1996-11-15 2000-03-21 L'oreal Nanoemulsion based on non-ionic and cationic amphiphilic lipids and uses thereof
US5925341A (en) * 1997-03-18 1999-07-20 L'oreal Nanoemulsion based on nonionic amphiphilic lipids and aminated silicones and uses
US6224853B1 (en) * 1997-04-22 2001-05-01 Woolcombers Group Plc Aqueous compositions comprising a lipid and a lanolin-derived surfactant, and their use
US7001602B2 (en) * 1997-07-15 2006-02-21 The Regents Of The University Of Colorado Use of botulinum toxin therapy for urinary incontinence and related disorders
US6265180B1 (en) * 1998-03-30 2001-07-24 Mibelle Ag Cosmetics Nanoemulsions for delivering lipophilic substances into cells
US6558941B2 (en) * 1998-03-30 2003-05-06 Mibelle Ag Cosmetics Delivering lipophilic substances into cells using nanoemulsions
US6589588B1 (en) * 1998-05-06 2003-07-08 Raisio Benecol Oy Phytosterol compositions
US5932562A (en) * 1998-05-26 1999-08-03 Washington University Sitostanol formulation to reduce cholesterol absorption and method for preparing and use of same
US6387411B2 (en) * 1998-11-30 2002-05-14 Mcneil-Ppc, Inc. Method for producing dispersible sterol and stanol compounds
US6573241B1 (en) * 1998-12-10 2003-06-03 BioteCon Gesellschaft für bio-technologische Entwicklung und Consulting GmbH Therapeutic agent for the suppression of snoring noises
US6274150B1 (en) * 1998-12-23 2001-08-14 L'oreal Nanoemulsion based on phosphoric acid fatty acid esters and its uses in the cosmetics, dermatological, pharmaceutical, and/or ophthalmological fields
US20020015721A1 (en) * 1999-01-05 2002-02-07 Jean-Thierry Simonnet Nanoemulsion based on ethylene oxide and propylene oxide block copolymers and its uses in the cosmetics, dermatological and/or ophthalmological fields
US20040009936A1 (en) * 1999-05-03 2004-01-15 Tang De-Chu C. Vaccine and drug delivery by topical application of vectors and vector extracts
US20050123897A1 (en) * 1999-07-05 2005-06-09 Idea Ag Method for the improvement of transport across adaptable semi-permeable barriers
US6358917B1 (en) * 1999-08-24 2002-03-19 Jean D. A. Carruthers Cosmetic use of botulinum toxin for treatment of downturned mouth
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6429189B1 (en) * 1999-12-10 2002-08-06 Botulinum Toxin Research Associates, Inc. Cytotoxin (non-neurotoxin) for the treatment of human headache disorders and inflammatory diseases
US20050124378A1 (en) * 1999-12-29 2005-06-09 Bellsouth Intellectual Property Corporation Portable communications device coupled to first network by way of second network
US20030157138A1 (en) * 2000-01-10 2003-08-21 Meir Eini Dermatological application with solidified fat compositions
US20030138465A9 (en) * 2000-01-21 2003-07-24 Veronique Douin Nanoemulsions comprising at least one amphiphilic lipid, at least one oil, and at least one nonionic polymer, and uses thereof
US20020098215A1 (en) * 2000-01-21 2002-07-25 Veronique Douin Nanoemulsions comprising at least one amphiphilic lipid, at least one oil, and at least one nonionic polymer, and uses thereof
US6869610B2 (en) * 2000-04-14 2005-03-22 Allergan Sales, Inc. Pain treatment by peripheral administration of a neurotoxin
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US20040028635A1 (en) * 2000-11-17 2004-02-12 Cedric Chauvierre Block-structure copolymer consisting of a saccharide segment bound to at least a biodegradable hydrophobic segment, and corresponding particles
US20020107199A1 (en) * 2000-12-05 2002-08-08 Allergan Sales, Inc. Methods of administering botulinum toxin
US20040081688A1 (en) * 2000-12-27 2004-04-29 Del Curto Maria Dorly Amphiphilic lipid nanoparticles for peptide and/or protein incorporation
US6902737B2 (en) * 2001-01-18 2005-06-07 L'oreal Translucent nanoemulsion, production method, and uses thereof in the cosmetic, dermatological and/or ophthalmological fields
US20040048836A1 (en) * 2001-03-23 2004-03-11 Wilmott James M Method for preparing high pressure/ high shear dispersions containing physiologically active ingredients
US20030072801A1 (en) * 2001-06-22 2003-04-17 Pfizer Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
US6890560B2 (en) * 2001-06-25 2005-05-10 Samyang Corporation Negatively charged amphiphilic block copolymer as drug carrier
US7226605B2 (en) * 2001-07-27 2007-06-05 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Botulinum toxin in the treatment or prevention of acne
US20050074466A1 (en) * 2001-07-27 2005-04-07 Suskind Dana L. Botulinum toxin in the treatment or prevention of acne
US20030108597A1 (en) * 2001-08-13 2003-06-12 Chancellor Michael B. Application of lipid vehicles and use for drug delivery
US20030077240A1 (en) * 2001-10-24 2003-04-24 Clariant International, Ltd. Use of high-purity phenylsilsesquioxane liquids for the preparation of cosmetic and pharmaceutical compositions
US20030086888A1 (en) * 2001-10-24 2003-05-08 Clariant International, Ltd Leave-on compositions for personal care
US20050065090A1 (en) * 2001-10-30 2005-03-24 Christian Ludin Dermopharmaceutically and cosmetically active oligopeptides
US7507419B2 (en) * 2001-12-18 2009-03-24 Coleman Iii William P Topically applied Clostridium botulinum toxin compositions and treatment methods
US20070116723A1 (en) * 2001-12-18 2007-05-24 Coleman William P Iii Topically applied clostridium botulinum toxin compositions and treatment methods
US20100040883A1 (en) * 2001-12-19 2010-02-18 Mccarthy Stephen P Polysaccharide-containing block copolymer particles and uses thereof
US7763663B2 (en) * 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
US20110020227A1 (en) * 2001-12-19 2011-01-27 University Of Massachusetts Polysaccharide-containing block copolmer particles and uses thereof
US20050118254A1 (en) * 2001-12-27 2005-06-02 Choi Jae M. Microemulsion preconcentrate
US6861066B2 (en) * 2002-03-11 2005-03-01 Health Plus International Inc. Method for the delivery of a biologically active agent
US20050147688A1 (en) * 2002-03-11 2005-07-07 Russell Van De Casteele Method for the delivery of a biologically active agent
US6688311B2 (en) * 2002-03-14 2004-02-10 Allergan, Inc. Method for determining effect of a clostridial toxin upon a muscle
US20040115159A1 (en) * 2002-03-29 2004-06-17 Tadlock Charles C Novel nanoemulsions
US20040037853A1 (en) * 2002-05-28 2004-02-26 Gary Borodic Composition for therapeutic and cosmetic botulinum toxin
US20040033202A1 (en) * 2002-06-10 2004-02-19 Elan Pharma International, Ltd. Nanoparticulate sterol formulations and novel sterol combinations
US20040003324A1 (en) * 2002-06-29 2004-01-01 Richard Uhlig Handling faults associated with operation of guest software in the virtual-machine architecture
US20050175636A1 (en) * 2002-07-11 2005-08-11 Stephen Donovan Transdermal patch for botulinum toxin administration
US20050074461A1 (en) * 2002-07-11 2005-04-07 Stephen Donovan Transdermal botulinum toxin compositions
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
US20040127661A1 (en) * 2002-09-12 2004-07-01 Harald Kaspar Fluoroelastomers having low temperature characteristics and solvent resistance
US20040115727A1 (en) * 2002-12-11 2004-06-17 Allergan, Inc., A Corporation Evolved clostridial toxins with altered protease specificity
US20040151741A1 (en) * 2002-12-20 2004-08-05 Gary Borodic Pharmaceutical botulinum toxin compositions
US20060165657A1 (en) * 2003-02-05 2006-07-27 Paul Bernasconi Method for delivery of cosmetic by topical application
WO2004076634A2 (en) * 2003-02-24 2004-09-10 Ira Sanders Cell membrane translocation of regulated snare inhibitors , compositions therefor, and methods for treatment of disease
US20050079228A1 (en) * 2003-05-30 2005-04-14 Ashish Jaiswal Clear, stable topical compositions of clarithromycin and processes for their preparation
US20060153877A1 (en) * 2003-06-20 2006-07-13 Shunji Kozaki Remedies for dissease with hypermyotonia
US20050005370A1 (en) * 2003-07-07 2005-01-13 The Procter & Gamble Company 2-(Amino or substituted amino)-5-(substituted oxymethyl)-phenol compounds, dyeing compositions containing them, and use thereof
US20050079131A1 (en) * 2003-08-08 2005-04-14 Lanza Gregory M. Emulsion particles for imaging and therapy and methods of use thereof
US7419996B2 (en) * 2003-08-13 2008-09-02 The University Of Houston Parenteral and oral formulations of benzimidazoles
US20050038096A1 (en) * 2003-08-13 2005-02-17 The University Of Houston Parenteral and oral formulations of benzimidazoles
US20050048088A1 (en) * 2003-08-28 2005-03-03 Fred Zulli Compositions comprising at least two nanoemulsions
US20050096340A1 (en) * 2003-10-29 2005-05-05 Yuehua Zhang Tocopherol-modified therapeutic drug compounds
US20040132667A1 (en) * 2003-11-17 2004-07-08 Sederma S.A.S Compositions containing mixtures of tetrapeptides and tripeptides
US20050136024A1 (en) * 2003-12-22 2005-06-23 Stockel Richard F. Dermatological compositions
US7228259B2 (en) * 2004-06-30 2007-06-05 Lucent Technologies Inc. Method and apparatus for structure-preserving reduced-order modeling
US20080050352A1 (en) * 2004-07-12 2008-02-28 Paul Webb Pharmaceutical Composition Comprising Botulinum, a Non Ionic Surfactant, Sodium Chloride and Sucrose
US20060018931A1 (en) * 2004-07-26 2006-01-26 Taylor Harold V Therapeutic composition with a botulinum neurotoxin
US20060073208A1 (en) * 2004-10-01 2006-04-06 Allergan, Inc. Cosmetic neurotoxin compositions and methods
US20060084353A1 (en) * 2004-10-18 2006-04-20 Wong Tak K Reversible ball having hyper-elastic properties
US20060182794A1 (en) * 2005-02-14 2006-08-17 Pankaj Modi Stabilized compositions for topical administration and methods of making same
US20070009555A1 (en) * 2005-06-14 2007-01-11 Borodic Gary E Botulinum toxin and the treatment of primary disorders of mood and affect
US20070036831A1 (en) * 2005-08-09 2007-02-15 Nanobio Corporation Nanoemulsion compositions having anti-inflammatory activity
US20070104743A1 (en) * 2005-11-09 2007-05-10 Hormos Medical Ltd. Formulations of fispemifene
US20070148194A1 (en) * 2005-11-29 2007-06-28 Amiji Mansoor M Novel nanoemulsion formulations
US20120164182A1 (en) * 2005-12-01 2012-06-28 University Of Massachusetts Botulinum nanoemulsions
US20100183726A1 (en) * 2006-08-02 2010-07-22 Robert Nicolosi Compositions and methods for treating cancer with dacarbazine nanoemulsions
US20100172943A1 (en) * 2006-12-01 2010-07-08 Anterios, Inc. Peptide nanoparticles and uses therefor
US20090041680A1 (en) * 2007-08-07 2009-02-12 Foamix Ltd. Wax Foamable Vehicle and Pharmaceutical Compositions Thereof

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
de Paiva et al. (FEBS 1990, 277(1,2), 171-174) *
Ludewig et al. (Adoptive Immunotherapy Methods and Protocols 2005, Humana Press Inc., NJ page 393) *
Montecucco et al. (Biochem J. 1989, 259, 47-53) *
Prescott (Methods in cell biology 1976, 14, page 34) *
Shone et al. (Eur. J. Biochem. 1987, 167, 175-180) *
Trotta et al. (International Journal of Pharmaceutics 2002, 241, 319-327) *
Verma et al. (Int. J. Pharmaceutics 2003, 141-151). *

Cited By (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8034378B2 (en) * 2002-12-27 2011-10-11 Novartis Vaccines And Diagnostics, Inc Immunogenic compositions containing phospholipid
US20040202669A1 (en) * 2002-12-27 2004-10-14 O'hagan Derek Immunogenic compositions containing phospholipid
US8541023B2 (en) 2002-12-27 2013-09-24 Novartis Vaccines And Diagnostics, Inc. Immunogenic compositions containing phospholipid
US10532019B2 (en) 2005-12-01 2020-01-14 University Of Massachusetts Lowell Botulinum nanoemulsions
US10576034B2 (en) 2005-12-01 2020-03-03 University Of Massachusetts Lowell Botulinum nanoemulsions
US10905637B2 (en) 2006-12-01 2021-02-02 Anterios, Inc. Peptide nanoparticles and uses therefor
US20100172943A1 (en) * 2006-12-01 2010-07-08 Anterios, Inc. Peptide nanoparticles and uses therefor
US9724299B2 (en) 2006-12-01 2017-08-08 Anterios, Inc. Amphiphilic entity nanoparticles
US9486409B2 (en) 2006-12-01 2016-11-08 Anterios, Inc. Peptide nanoparticles and uses therefor
US10285941B2 (en) 2006-12-01 2019-05-14 Anterios, Inc. Amphiphilic entity nanoparticles
US10758485B2 (en) 2006-12-01 2020-09-01 Anterios, Inc. Amphiphilic entity nanoparticles
US10016451B2 (en) 2007-05-31 2018-07-10 Anterios, Inc. Nucleic acid nanoparticles and uses therefor
US10293034B2 (en) * 2007-07-10 2019-05-21 Medy-Tox, Inc. Pharmaceutical liquid composition of botulinum toxin with improved stability and method of use
US20140161783A1 (en) * 2007-07-10 2014-06-12 Medy-Tox, Inc. Pharmaceutical Liquid Composition of Botulinum Toxin With Improved Stability
US9220780B2 (en) * 2007-07-10 2015-12-29 Medy-Tox Inc. Pharmaceutical liquid composition of botulinum toxin with improved stability
US20090214685A1 (en) * 2008-02-22 2009-08-27 Hunt Terrence J Sustained release poloxamer containing pharmaceutical compositions
US9107815B2 (en) * 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
US9278140B2 (en) 2008-02-22 2016-03-08 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
US9981022B2 (en) 2008-02-22 2018-05-29 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
US20110206739A1 (en) * 2008-03-28 2011-08-25 University Of Massachusetts Compositions and methods for the preparation of nanoemulsions
US20110212157A1 (en) * 2008-06-26 2011-09-01 Anterios, Inc. Dermal delivery
WO2012103035A1 (en) * 2011-01-24 2012-08-02 Anterios, Inc. Nanoparticle compositions
WO2012103037A1 (en) * 2011-01-24 2012-08-02 Anterios, Inc. Oil compositions
EP3572072A1 (de) * 2011-01-24 2019-11-27 Anterios, Inc. Nanopartikelzusammensetzungen
US8183227B1 (en) 2011-07-07 2012-05-22 Chemo S. A. France Compositions, kits and methods for nutrition supplementation
US8545896B2 (en) 2011-09-29 2013-10-01 Chemo S. A. France Compositions, kits and methods for nutrition supplementation
US8168611B1 (en) 2011-09-29 2012-05-01 Chemo S.A. France Compositions, kits and methods for nutrition supplementation
US10487107B2 (en) 2011-10-03 2019-11-26 Mx Adjuvac Ab Nanoparticles, process for preparation and use thereof as carrier for amphipatic and hydrophobic molecules in fields of medicine including cancer treatment and food related compounds
US10100078B2 (en) 2011-10-03 2018-10-16 Mx Adjuvac Ab Nanoparticles, process for preparation and use thereof as carrier for amphipatic and hydrophobic molecules in fields of medicine including cancer treatment and food related compounds
US10047116B2 (en) * 2011-10-03 2018-08-14 Mx Adjuvac Ab Nanoparticles, process for preparation and use thereof as carrier for amphipatic and hydrophobic molecules in fields of medicine including cancer treatment and food related compounds
US20140234349A1 (en) * 2011-10-03 2014-08-21 Moreinx Ab Nanoparticles, process for preparation and use thereof as carrier for amphipatic and hydrophobic molecules in fields of medicine including cancer treatment and food related compounds
WO2013063279A1 (en) * 2011-10-25 2013-05-02 The Trustees Of Princeton University A high-loading nanoparticle-based formulation for water-insoluble steroids
US9737518B2 (en) 2013-04-01 2017-08-22 Pulmatrix Operating Company, Inc. Tiotropium dry powders
WO2015200054A3 (en) * 2014-06-24 2016-03-17 The Trustees Of Princeton University Process for encapsulating soluble biologics, therapeutics, and imaging agents
US11554101B2 (en) 2014-06-24 2023-01-17 The Trustees Of Princeton University Process for encapsulating soluble biologics, therapeutics, and imaging agents
US10231937B2 (en) 2014-06-24 2019-03-19 The Trustees Of Princeton University Process for encapsulating soluble biologics, therapeutics, and imaging agents
CN104083340A (zh) * 2014-07-29 2014-10-08 厦门大学 一种包埋维a酸的聚乳酸载药微球的制备方法
US11179305B2 (en) 2015-08-10 2021-11-23 Mary Kay Inc. Topical compositions
US10722436B2 (en) 2015-08-10 2020-07-28 Mary Kay Inc. Topical compositions
US11103461B2 (en) 2015-12-22 2021-08-31 The Trustees Of Princeton University Process for encapsulating soluble biologics, therapeutics, and imaging agents
US10973890B2 (en) 2016-09-13 2021-04-13 Allergan, Inc. Non-protein clostridial toxin compositions
US11311496B2 (en) 2016-11-21 2022-04-26 Eirion Therapeutics, Inc. Transdermal delivery of large agents
US20200009040A1 (en) * 2017-02-07 2020-01-09 Myocept Inc. Topical formulations and methods
WO2018148338A1 (en) * 2017-02-07 2018-08-16 Lars Erik Peters Topical formulations and methods
US11752086B2 (en) * 2017-02-07 2023-09-12 Myocept Inc. Topical formulations and methods
US11737981B2 (en) 2017-09-12 2023-08-29 The Trustees Of Princeton University Cellulosic polymer nanoparticles and methods of forming them
WO2019113044A1 (en) * 2017-12-07 2019-06-13 Ps Therapies Ltd Topical compositions and methods of use thereof
CN112236120A (zh) * 2018-01-15 2021-01-15 定制脚本有限公司 用于个性化营养配方和递送系统的系统、方法、组成和装置
US11854678B2 (en) * 2018-01-15 2023-12-26 Hygieia Health Co., Limited Systems, methods, compositions and devices for personalized nutrition formulation and delivery system
US20190221299A1 (en) * 2018-01-15 2019-07-18 Hygieia Health Co., Limited Systems, methods, compositions and devices for personalized nutrition formulation and delivery system
WO2019140432A1 (en) * 2018-01-15 2019-07-18 Hygieia Health Co., Limited Systems, methods, compositions and devices for personalized nutrition formulation and delivery system
US11731099B2 (en) 2018-07-20 2023-08-22 The Trustees Of Princeton University Method for controlling encapsulation efficiency and burst release of water soluble molecules from nanoparticles and microparticles produced by inverse flash nanoprecipitation
US20220192983A1 (en) * 2019-04-19 2022-06-23 Sila S.R.L. Granular product based on arginine
CN111826021A (zh) * 2020-06-12 2020-10-27 西北工业大学深圳研究院 一种基于纳米氢氧化钙的壁画表面聚丙烯酸树脂清除用有机凝胶及其制备方法
CN114874702A (zh) * 2022-05-27 2022-08-09 广东红日星实业有限公司 一种抛光蜡及其制备方法和应用

Also Published As

Publication number Publication date
US20190298654A1 (en) 2019-10-03
WO2008070538A2 (en) 2008-06-12
US20210220271A1 (en) 2021-07-22
CN101848702A (zh) 2010-09-29
JP2014031382A (ja) 2014-02-20
SG177184A1 (en) 2012-01-30
US9724299B2 (en) 2017-08-08
JP2010528981A (ja) 2010-08-26
US20170360704A1 (en) 2017-12-21
EP2494958A1 (de) 2012-09-05
US20140161854A1 (en) 2014-06-12
EP2099429A2 (de) 2009-09-16
CN101848702B (zh) 2013-07-17
MX2009005727A (es) 2009-08-27
AU2007329579A1 (en) 2008-06-12
BRPI0719756A2 (pt) 2014-01-21
US10285941B2 (en) 2019-05-14
KR20090106493A (ko) 2009-10-09
US10758485B2 (en) 2020-09-01
CA2671447A1 (en) 2008-06-12
WO2008070538A3 (en) 2008-11-06

Similar Documents

Publication Publication Date Title
US10758485B2 (en) Amphiphilic entity nanoparticles
US20220175634A1 (en) Peptide nanoparticles and uses therefor
AU2017360346B2 (en) Transdermal delivery of large agents
WO2008151022A2 (en) Nucleic acid nanoparticles and uses therefor
EP3890704A1 (de) Verbesserte abgabe von grossen wirkstoffen
AU2013204319B2 (en) Peptide nanoparticles and uses therefor

Legal Events

Date Code Title Description
AS Assignment

Owner name: ANTERIOS, INC.,NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:KOTYLA, TIMOTHY;REEL/FRAME:022701/0786

Effective date: 20090213

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION